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Résumé 
Les anthracyclines tels que la doxorubicin et la daunorubicin sont une famille de médicaments 
anticancéreux hydrophiles qui doivent être transportés dans les cellules afin d’exercer leur 
action par intercalation à l’ADN dans le noyau cellulaire. Ceci mène à la perturbation du 
métabolisme de l’ADN et entraine la mort cellulaire. Les anthracyclines sont utilisés pour le 
traitement d’une variété de cancers incluant la leucémie, les lymphomes, le cancer du sein, le 
cancer des poumons et le cancer des ovaires. Étant donné que le transport actif des 
anthracyclines dans les cellules a partiellement été démontré, le transporteur spécifique 
impliqué dans ce processus n’est pas encore connu. En utilisant un modèle de cancer des 
ovaires, la lignée cellulaire TOV2223G, nous avons démontré que des substrats spécifiques au 
transporteur de cations organiques 1 (OCT1), notamment la ergothionéine, la thiamine et la 
phenformin, ont partiellement inhibé l’absorption de la daunorubicin en différence de la 
carnitine qui est un substrat de haute affinité des transporteurs CT2 et OCTN2. Ces résultats 
suggèrent que les transporteurs organiques spécifiques au transport de la carnitine ne sont pas 
impliqués dans le transport des anthracyclines. Ainsi, nos résultats ont démontré que 
l’absorption de la daunorubicin est orchestrée par le transporteur OCT1 dans les cellules 
TOV2223G (Km ~ 5 μM) et des concentrations micromolaires de choline ont complètement 
abolies l’absorption de la drogue. De plus, un ARN sh dirigé contre OCT1 a réprimé son 
expression protéique, ce qui a été confirmé par la technique d’immuno-buvardage en utilisant 
un anti-OCT1 anticorps. Les cellules déficientes en OCT1 n’ont pas été capables d’absorber la 
daunorubicin et ont été plus résistantes à l’action de la drogue par rapport aux cellules 
contrôle. La transfection des cellules HEK293T avec un plasmide construit de façon à faire 
exprimer OCT1 comme protéine de fusion avec la protéine fluorescente EYFP a montré que 
celle-ci est localisée dans la membrane plasmique. Les cellules transfectées ont été capables 
d’absorber cinq fois plus de daunorubicin comparé aux cellules contrôles. Cette étude est, 
selon nous, la première à démontrer que OCT1 est un transporteur de haute affinité des 
anthracyclines. Ainsi, nous avons émis l’hypothèse que des défauts de OCT1 peuvent 
contribuer à l’efficacité de la réponse des cellules cancéreuses à la chimiothérapie avec les 
anthracyclines.   
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Abstract 
Anthracyclines such as doxorubicin and daunorubicin are hydrophilic anticancer agents 
that must be transported into cells.  These drugs accumulate in the nucleus where they 
intercalate with DNA, thereby interfering with DNA replication in turn leading to cell death.  
Anthracyclines are used for treating a variety of cancers including leukemia, lymphomas, 
breast, lung, and ovarian. Despite evidence for active uptake of anthracyclines, the specific 
transporter has not been identified.  Using the ovarian cancer cell line TOV2223G, we show 
that substrates reported for the organic cation transporter OCT1, such as ergothioneine, 
thiamine and phenformin, partially compete with uptake of daunorubicin, but not of L-
carnitine, i.e., a high affinity substrate transported by hCT2 and OCTN2.  These findings 
exclude the involvement of the L-carnitine organic cation family of transporters in 
anthracycline uptake.  Moreover, we show that OCT1 actively mediates high affinity (Km ~ 5 
μM) transport of daunorubicin into TOV2223G cells, whereas micromolar amounts of choline 
completely abolish drug uptake.  shRNA-mediated downregulation of OCT1 causes defective 
uptake of daunorubicin, as well as significant resistance to the drug, as compared to the vector 
control.  Transfection of HEK293T cells with a plasmid expressing OCT1 as a GFP fusion 
protein revealed that OCT1-EYFP was predominantly localized to the plasma membrane.  
These transfected cells manifested nearly 5-fold increased uptake of daunorubicin compared to 
the empty vector control.  In summary, we show for the first time that human OCT1 is a high 
affinity transporter for anthracyclines.  As such, we postulate that OCT1 status represents a 
critical determinant in the response of cancer cells to chemotherapy with anthracyclines 
Keywords: Human organic cation transporter 1(OCT1), anthracyclines 
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Chapter 1: Introduction 
1. Chemotherapy and DNA-damaging agents 
Cancer is a complex disease that is characterized by deregulated cell proliferation caused by 
various factors including genetic and environmental (1). Currently, cancer is responsible for 
more than seven million deaths worldwide according to statistics from the World Health 
Organization. The battle with cancer has been led for more than four decades as all began with 
the War on Cancer with the President Nixon’s National Cancer Act of 1971 (2). Despite the 
increasing success of recently introduced novel cellular therapies, such as hematopoietic stem 
cell transplantations, treatment of cancer is still widely based on the use of chemotherapeutic 
agents to eradicate cancer cells, to reduce tumor growth, and to ameliorate patient’s quality of 
life. During the World War I and II, when studying victims exposed to sulfur mustard gas, 
important discoveries were made using mice as a model. By injecting stable nitrogen mustard 
compounds, it was observed an important tumor regression. Moreover, leukemia patients 
treated with folic acid showed increased proliferation of acute lymphoblastic leukemia cells 
(1). This has led to the discovery of folate analogs such as aminopterin whose action led to 
successful, yet short, remissions. Nonetheless, the most important role of these compounds 
was finally established and that consisted of damaging DNA (1). However, it took another ten 
years before the discovery of the exact mechanisms by which these compounds caused DNA 
damage. Hence, it was established that nitrogen mustard act by directly alkylating DNA on 
purine bases. Based on this mechanism, derivatives such as cyclophosphamide, chlorambucil 
and melphalan were developed. In addition, platinum agents possessing DNA alkylating 
capabilities were also discovered and led to a new era of anticancer drug research. It all began 
with the accidental discovery of cisplatin by Rosenberg et al., (3) followed by the development 
of other platinum derivatives such as carboplatin and oxaliplatin (4). However, cisplatin 
remains the most used platinum drug and cisplatin therapy succeeds to treat more than 90% of 
all testicular cancer patients, and has a good efficacy in treating ovarian, bladder, and head and 
neck cancers (5). A second mechanism of DNA damage is the interference with DNA 
replication, and antimetabolites which are part of anticancer drugs, have the ability to mimic 
endogenous cellular molecules. Such antimetabolites are the pyrimidine analogs 5-fluorouracil 
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(5-FU), gemcitabine, floxuridine, and capecitabine whose action consists of incorporating 
purine and pyrimidine analogs into DNA during S phase which in turn prevents addition of 
normal nucleobases leading to abrogation of DNA replication (1). Lastly, a third mechanism 
of DNA damage is interference with the normal DNA function by targeting protein-DNA 
complexes. Topoisomerases are a class of enzymes that participate in the release of the 
torsional strain of the DNA double helix (1, 6). Topoisomerases act by causing transient single 
strand breaks (topo I) or double strand breaks (topo II) (6). Topoisomerase poisons have the 
ability to trap the complex formed by DNA –enzyme as intermediate which prevents religation 
of the break leading to multiple alterations in DNA transactions such as replication fork 
progression in turn causing fatal double strand breaks (DSBs) (1, 6) . Anthracyclines represent 
a very important class of anticancer drugs that act as topoisomerase II poison and are the most 
effective anticancer agents ever used in treatment of  a variety of cancers (7). 
1.1. Anthracyclines 
The first anthracyclines, i.e., daunorubicin (DNR) and doxorubicin (DOX), were isolated in 
1960 form Streptomyces peucetius. DNR (trade name Cerubidine) and DOX (trade names 
Adriamycin and Rubex) have similar structures characterized by aglyconic and sugar moieties. 
The aglyconic structure consists of a tetracycline backbone attached to the sugar moiety 
referred to as daunosamine by a glycosidic bond. DOX and DNR differ structurally only at C-
14, terminating with alcohol and methyl groups respectively (figure 1, indicated with arrows) 
(6, 8) 
 
 
Figure1. Chemical structure of DOX and DNR. Adapted from (6) 
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1.2. Anthracyclines as topoisomerase inhibitors 
Anthracyclines kill cancer cells by several mechanisms including (i) DNA intercalation and 
thus interference with DNA replication, (ii) generation of reactive oxygen species (ROS) 
which damage DNA and other cellular macromolecules, (iii) poisoning topoisomerase II (topo 
II),  and (iv) interference with DNA unwinding and helicase activity (6). Interference with 
topo II activity consists of modifying DNA topology without affecting DNA structure or 
sequence. As mentioned above, topoisomerases act by causing transient single strand breaks 
(topo I) or double strand breaks (topo II) (6). Numerous studies have focused on drugs 
targeting topo II such as etoposide. This drug “traps” topo II at break sites, i.e., stabilizes the 
cleavage complex by blocking the DNA ligation step. Anthracyclines are believed to act 
similarly to etoposides; for example, topo II activity correlates with the anticancer efficiency 
of anthracyclines in a mouse model of lymphoma (9). However, DOX was shown to trigger 
cell death independently of topo II in a promyelocytic leukemic cell line where it rather 
resulted in histone eviction (9). Anthracyclines intercalate into DNA at sites adjacent to GC 
base pairs due hydrogen bond formation with guanine, leading to the formation of DNA 
adducts which are characterized as DNA fragments bound to an antineoplastic agent. 
Moreover, anthracycline-DNA interactions are stabilized by formation of covalent bonds 
mediated by cellular formaldehyde and generated by free radical reactions that result from 
carbon sources supplied by lipids and spermine. As a result, anthracyclines form a covalent 
bond on one strand of the DNA and a hydrogen bond with guanine on the opposite strand (9). 
1.3. Anthracyclines and ROS formation 
The entry of the anthracyclines in the cell is accompanied by the addition of one-electron to 
the quinone moiety present in ring C (figure 1) which results in the formation of semi-quinone. 
Regeneration of quinone is followed by reducing oxygen to superoxide anion and hydrogen 
peroxide (6). This formation is maintained by a number of NADPH-oxidases including 
mitochondrial NADPH, cytochrome P450 and others. Moreover, a further contribution of the 
semi-quinone is to oxidize the bond between ring A and the sugar moiety daunosamine which 
results in a deglycosylation followed by the formation of deoxyglycone. This process is 
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believed to confer more lipid solubility which allows the anthracyclines to easily incorporate 
into biological membranes creating reactive oxygen species (10), (6). 
 
1.4. Anthracyclines and cardiotoxicity  
Despite the effectiveness of anthracyclines as anticncer drugs, there are important limitations, 
particularly cardiac toxicity in the form of myocyte damage, reduced contractility, and total 
cardiac failure (11). Hefti et al., (12), reported that multiple processes are involved in 
cardiomyocyte dysfunction, including the implication of first stage alcohol metabolites in the 
disruption of iron and calcium homeostasis. This alters mitochondrial calcium release which, 
as a consequence, impairs mitochondrial creatine kinase activity. Overall, perturbed 
mitochondrial function is believed to underlie severe cardiomyocyte deregulation. 
Cardiomyocyte failure is further promoted by release of anthracycline-induced ROS coupled 
with a substantial decreases in the level of detoxifying enzymes such as superoxide dismutase 
and deregulation of nitric oxide production (12).  
1.5. Novel generations of Anthracyclines  
To counteract anthracycline toxicity, new semi-synthetic and synthetic formulations have been 
produced for approval by the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA). Only few semisynthetic anthracyclines derivatives, i.e., idarubicin, epirubicin, 
pirarubicin, aclarubicin and mitoxanthrone, have obtained such approval (figure 2). Idarubicin, 
derived from DNR, appears to be more effective than DNR in several aspects including 
increased liposolubility and oral administration (13). Epirubicin, a close relative to DOX, has 
been used mostly in treatment of breast cancer with relatively good success especially when in 
combination with cyclophosphamide and 5-fluorouracil. However, similar to DNR and DOX, 
epirubicin induces significant cardiotoxicity (8). A study in rats investigated the effectiveness 
of pirarubicin, another close relative of DOX. The former manifested significantly lower 
cardiotoxicity, but cancer cell killing was also less effective compared to DOX (Adriamycin) 
(14). Aclarubicin and aclamycin were also shown to display only a relatively modest 
cardiotoxicity improvement over DNR and DOX. Mitoxanthrone which is similar to DOX has 
 17 
 
been extensively tested for treatment of breast cancer, prostate cancer and leukemia because of 
reduced cardiotoxicity. Nonetheless, Thomas and coworkers reported that mitoxanthrone 
induces cardiotoxicity levels similar to DOX and DNR (6, 15) 
 
 
                               Mitoxanthrone 
 
Figure 2. Chemical structures of various anthracyclines derivatives. 
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2. Transporters of Anthracyclines 
Anthracyclines are positively charged drugs that must be actively transported into and out of 
cells. Numerous studies have revealed two major families of anthracycline transporters which 
will be discussed here in some detail: (i) the ATP-binding cassette family (ABC) and (ii) the 
organic cation transporters (OCTs). In addition, the organic anion transporters (OATs) will 
also be reviewed briefly since they are part of SLC22 subfamily and have been reported to 
interact with typical OCT substrates. 
 
2.1. ATP-binding cassette family (ABC) 
The ABC transporter family has a role in tissue protection against toxic compounds including 
endogenous metabolites and exogenous xenobiotics. They have also garnered attention for 
their role in chemoresistance (16). This family of transporters consists of seven subfamily 
members designated A to G and are encoded by 48 genes (17). They display broad tissue 
distribution and are present in key physiological barriers such as the biliary canalicular 
membrane of hepatocytes, apical membrane of the proximal tubules of the kidney, brush 
border membrane of intestine and epithelium of the blood-brain barrier (17). Various studies 
have established that among all ABC transporters, only 12 members belonging to 4 
subfamilies exert an important role in drug resistance (17). 
2.1.1. The ABCB subfamily transporters 
The ABCB subfamily of transporters, also known as multidrug resistance (MDR) proteins,  
includes the well characterized P-glycoprotein which transports mostly anionic compounds 
(16), but also various positively charged antineoplastic drugs such as anthracyclines, taxanes 
and vinca alkaloids. P-glycoprotein is expressed in various tissues such as liver, kidney and 
intestine, as well as specialized stem cells of the immune system (17). Moreover P-
glycoprotein is expressed in the blood-brain barrier which prevents access of many 
xenobiotics to the central nervous system (18). Such xenobiotics have been reported to 
modulate P-glycoprotein. For example, it was reported that cationic (hydrophilic) compounds 
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can strongly compete with hydrophobic ones, thereby acting as either inhibitors or inducers of 
P-glycoprotein. Some drugs that specifically inhibit P-glycoprotein interact with digoxin 
leading to toxic accumulation of this cardiac glycoside. To prevent this accumulation, inducers 
of P-glycoprotein are required (18). There are two types of P-glycoprotein inhibitors: calcium 
channel blockers and beta blockers. Examples of the former type include nicardipine, 
verapamil, diltiazem, nifedipine, while the latter type includes carvedilol, bisoprolol, 
propranolol (18). 
2.1.2. The ABCC subfamily transporters 
The ABCC subfamily transporters, known as multidrug resistance-associated proteins 
(MRPs), differ structurally from ABCB counterparts in possessing additional domains aside 
from the common nucleotide binding- and transmembrane-domains. In fact, some members of 
the ABCC1, ABCC2, ABCC3, ABCC6 and ABCC10 subfamilies possess an N-terminal 
membrane domain attached to the core structure by a cytoplasmic linker, whereas ABCC4, 5, 
11 and 12 lack an N-terminal domain but retain the cytoplasmic linker (17). ABCC 
transporters also differ in the ability to transport negatively charged compounds. This 
evolutionary property of the ABCC transporters confers improved protection from differently 
charged toxic biomolecules (17).  
2.1.3. The ABCG subfamily transporters 
ABCG subfamily transporters contains, among others, their most important member involved 
in drug resistance, i.e., ABCG2 efflux transporter also known as MXR or BCRP (17). ABCG2 
was first discovered based on its ability to transport mitoxanthrone and it was reported that 
this substrate is not transported either by P-gp or MRP1 (19). Unlike P-glycoprotein which 
more selectively transports negatively charged compounds, ABCG2 can transport either 
negatively or positively charged compounds. It was reported that unlike P-glycoprotein, 
ABCG2 cannot transport key substrates such as verapamil, taxols, imatinib, Vinca alkaloids 
and anthracyclines (17). Figure 3 presents an overview of some of the ABC transporters and 
their localization in various tissues. 
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Figure 3 Schematic representation of the ABC transporter localization in liver (hepatocytes), 
kidney (proximal tubule cells) and blood-brain barrier (brain endothelial cells). Adapted from 
(20). 
 
2.2. Mechanism of transport by ABC transporters 
Drug transport by ABC family members consists of two stages: ATP hydrolysis which 
activates transport, followed by export of the compound from the cytoplasm to the 
extracellular space. However, the exact mechanism by which the binding and subsequent 
transport occur remain unclear (16). The following mechanism has been proposed: ATP-
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dependent drug binding (first stage) is followed by physical translocation from the cytoplasm 
to the extracellular space (second stage). In the first stage, ATP binding occurs in the 
nucleotide binding domain, consisting of three highly conserved sequences and the signature 
C motif.  All ABC transporters display high ATPase activity in the micromolar range, but low 
affinity for ATP in the millimolar range (16). The second stage is highly dependent on the 
structure presented by the transporter. For example, P-glycoprotein (ABCB1) has 12 
transmembrane domains and 2 nucleotide binding domains while ABCG2 displays only half 
of both. This suggests that the latter is likely to homodimerize. Because of its function in 
expelling toxic compounds outside the cell, the substrate binding site is located on the 
cytoplasmic side of the plasma membrane and consists of transmembrane helices which form 
a binding pocket (16). Studies have revealed that additional binding minipockets are located 
adjacent to the main binding pocket, together forming a funnel-like shape with the narrowest 
part facing the cytoplasm. Two co-substrates can easily enter the narrow opening and 
determine either massive and rapid efflux of the targeted compound or its inhibited transport 
regulated by the binding of the inhibitor substrate (16). 
 
3. Organic cation transporters (OCTs and OCTNs) 
OCTs belonging to the SLC22 family are part of the major, highly-conserved facilitator 
superfamily (MFS) of transporters (20). OCTs include two subclasses based on substrate 
specificity:1) OCT1, OCT2, and OCT3 and 2) zwitterion/cation transporters OCTN1, OCTN2, 
OCTN3 and CT2/OCT6 (20, 21).  The OCTs subgroup (OCT1-3) exhibits close similarity in 
substrate specificity and transport mechanism. They all translocate various cations across the 
plasma membrane. The subclass of OCTNs (OCTN1, OCTN2 and CT2) are either uniporters 
of cations and zwitterions, and differ from OCTs in their ability to transport carnitine to the 
peroxisome for beta oxidation  in a sodium-dependent manner (symport mechanism) (20). 
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3.1. OCT1 
OCT1 (gene number SLC22A1) is located on chromosome 6. The first characterization of 
OCT1 was carried out by Gründemann et al., (22). Using a Xenopus oocyte-based expression 
system, this group successfully isolated OCT1 cDNA from a rat kidney library. The reported 
clone contained an open reading frame encoding a plasma membrane protein of 61.5 kDa. 
Overexpression of this protein in oocytes was shown to correlate with increased uptake of 
tetraethyl ammonium (TEA) with Km of approximately 100µM (22). Despite evidence that 
TEA transport by OCT1 is potential-dependent, it was shown that inwardly or outwardly 
proton gradients of 1 pH unit do not alter significantly  uptake of this substrate (22). In mouse 
and rabbit, using RT-qPCR, mRNA levels were detected in kidney and to a lesser extend in 
liver (20). In humans, OCT1 is predominantly expressed in liver and less so in kidney. hOCT1 
mRNA levels are also detected in the immune system and various organs such as small 
intestine, heart, skeletal muscle, brain, eye, placenta and others (20). 
 
 
3.1.1. OCT1 as metformin transporter 
Metformin belongs to the class of the biguanides that are used to treat type 2 diabetes; indeed, 
this drug efficiently reduces gastrointestinal glucose absorption and glucose production in the 
liver (23) (24). Metformin is initially activated through phosphorylation by AMP-activated 
protein kinase which in turn greatly reduces glucose production in hepatocytes thus leading to 
enhanced uptake of circulating glucose by the muscle and hepatocytes (24). OCT1 is a 
determinant of metformin uptake and it was reported that variations in response to metformin 
are attributable to genetic variants of OCT1 as reported by Shu et al., (24). The authors 
reported that several genetic variants displayed normal uptake of the model OCT1 substrate 1-
methyl-4-phenylpyridinium (1-MPP), but greatly reduced metformin uptake suggesting the 
determinant role of OCT1 in the transport of metformin. 
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3.1.2. OCT1 as thiamine transporter 
Chen et al.,(23) reported that OCT1 is a high capacity thiamine transporter. Thiamine is 
transported by two high affinity transporters belonging to the SLC19 family, i.e., members 2 
and 3 which act in sodium-dependent manner. However, using both human and mouse hepatic 
cells, the authors reported that OCT1 retains the ability to take up thiamine with high affinity. 
This seems consistent with the fact that thiamine is directed to the liver where OCT1 is 
predominantly expressed, and particularly in the central vein where important metabolic 
reactions occur. 
3.1.3. OCT1 as donepezil transporter 
 Kim et al., (25) reported that OCT1 has an important role in transport of donepezil, a 
therapeutic agent for Alzheimer’s disease which is characterized by progressive degeneration 
of cholinergic neurons. Donepezil is a cholinesterase inhibitor which acts similarly to tacrine 
by increasing levels of the neurotransmitter acetylcholine in the presynaptic cleft of the 
cholinergic neurons. It was shown in rat brain, that donepezil is taken up with high affinity by 
CHT1 and OCT1 and to a lesser extent by other organic cation/zwitterion transporters such as 
OCT2 and OCTN2 (25). CHT1 (CHoline Transporter 1), is the main transporter for 
acetylcholine in neurons and manifests the highest affinity for donepezil. However, Murakami 
et al., (26) showed that CHT1 is a close relative to OCT1 in terms of substrate specificity, and 
also reported  that CHT1 in the blood-brain barrier might in fact be an isoform of the OCTs 
family (26) 
3.1.4. OCT1 as choline transporter 
Choline plays an important role in cell homeostasis by providing phospholipid compounds for 
the plasma membrane. In addition, it is involved in methionine metabolism as a methyl donor 
and in neurotransmission by providing acetylcholine (27). Moreover, deficiency in choline is 
associated with various neuronal and hepatic disorders and is also linked to various cancers 
(27). Choline is transported by three systems based on tissue localization and substrate 
affinity. The highest affinity choline transporter is CHT1, which delivers acetylcholine in 
cholinergic neurons. The role of the organic cation transporters OCT1 and OCT2 in choline 
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transport is however unclear and results vary from study to study (27). For example, 
overexpression of either OCT1 or OCT2 in human embryonic kidney HEK293T cells revealed 
increased uptake of choline by OCT1, but not by OCT2 (28). Another study showed that both 
OCTs were efficient in choline uptake in Xenopus oocytes (29). Various reports also claim 
considerable variability of the Michaelis-Menten affinity constant ranging from 100µM to 350 
µM for either OCT1 or OCT2 (27). However, the evidence for OCT1 as a donepezil 
transporter in rat brain supports its role in choline and/or acetylcholine uptake in both neuronal 
and non-neuronal cells (25); nonetheless more studies are needed to determine whether OCT1 
is indeed able to transport choline independently of CHT1 and/or OCT2.  
3.1.5. OCT1 as transporter for anticancer drugs 
Anticancer therapy outcome depends on the activity of the anticancer agent and the cellular 
machinery (30). For example, platinums such as picoplatin, oxaliplatin and cisplatin activities 
lead to differences in the formation of DNA adducts depending on the activity of the 
nucleotide excision repair mechanism to repair the resulting DNA damage. Thus, the 
cytotoxicity effect of this formation depends on the cellular expression of transporter proteins 
for these platinum drugs. More et al., (30) demonstrated that expression of OCT1, OCT2, but 
not OCT3 significantly enhances the uptake of  picoplatin and the resulted formation of DNA 
adducts. Disposition of picoplatin (i.e. absorption, distribution, metabolism and excretion) was 
shown not to be dependent on OCT1 expression as demonstrated by pharmacokinetic studies 
(30). It also was shown that OCT1 expression greatly influences oxaliplatin uptake, but not 
carboplatin or cisplatin in two independent studies done by Zhang et al., (31) and Yokoo et al., 
(32). OCT1 expression levels were also demonstrated to correlate with imatinib action in 
treating patients with chronic myelogenous leukemia (CML) as shown by White et al., (33). 
Taxanes such as paclitaxel are important class of drugs whose action interferes with 
microtubule proper function leading to deregulation in mitosis (34). The role of OCT1 in the 
transport of paclitaxel was investigated by Gupta et al., (35) who demonstrated that OCT1 
expression in model lymphoma cell lines and in primary chronic lymphocytic leukemia 
patients samples is a determinant of enhanced paclitaxel uptake. Moreover, the authors 
investigated the uptake of another anticancer agent- irinotecan, and found that OCT1 
expression pattern influences the efficacy of treatment with this particular agent (35).  
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3.2. OCT2 
OCT2 (gene number SLC22A2) was first cloned in 1996 by Okuda et al. (36) from rat. 
Functional analysis of the open reading frame revealed that rOCT2 is a membrane protein 
containing twelve membrane spanning helices with an extracellular loop between helices 1 
and 2 and two glycosylation sites. The extracellular loop, which contains the substrate binding 
pocket, was reported to be highly similar to rOCT1 with 85% identity. The authors also 
identified four potential phosphorylation sites for protein kinase A and two phosphorylation 
sites for protein kinase C. By injecting OCT2 cRNA in Xenopus oocytes, uptake studies with 
TEA showed a marked increase in transport rate that was greatly decreased in the case of 
cimetidine, quinidine, and procainamide. By varying the pH, it was established that OCT2 acts 
independently of proton gradient and/or environmental pH (36). Further studies investigating 
the role of OCT2 revealed that this transporter mediates, among others, electrogenic transport 
of various organic cations such as N-methyl-nicotinamide and choline (37). A study from 
Mitohashi et al., (38) reported that human OCT2 is the main transporter in kidney and is 
similar to rat OCT2 which is localized on the basolateral membrane of proximal tubules. 
Moreover, immunohistochemistry studies on human OCT2 also showed basolateral membrane 
localization (38). However, there was a discrepancy over OCT2 localization from that study 
and a study from Gorboulev et al., (39) that showed OCT2 being localized on the apical 
membrane in distal tubules of human kidney. The marked difference was associated with the 
antibody which apparently displayed some cross-reactivity with closely related transporters in 
the same region (38). Several other studies investigating the role and behavior of OCT2 have 
also been conducted. In terms of substrate binding and stability, Barendt et al., (40) showed 
that among all organic cation transporters, interactions between substrates and OCT2 are 
greatly influenced by the charge in such way that when there were variations in the pH of the 
environment, an increase or a decrease of a protonated fraction of a substrate was observed. 
This, in consequence, affected the binding properties of substrates for OCT2. However, these 
changes did not affect the model substrates TEA and 1-MPP (40). Aside from its role in 
kidney, OCT2 was found in the brain where it participates in the transport of corticosterone 
(41). Although uptake of this steroid is mainly transported by extra neuronal monoamine 
transporter or EMT (see OCT3/EMT), the authors noted that OCT2 and OCT3 are not 
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identical and can be distinguished pharmacologically by use of O-methyllisoprenaline which 
appears to inhibit potently EMT, but not OCT2 (41). OCT2 can also transport several 
neurotransmitters, but most importantly dopamine in both kidney and brain. Evidence for 
OCT2 involvement in dopamine clearance came from a study reporting that proximal and 
distal tubules were able to express dopamine synthesizing enzyme L-aromatic amino acid 
decarboxylase. In support of this, cells forming the proximal tubules are known to produce 
dopamine which is believed to act as natriuretic hormone (41).  
3.2.1. OCT2 as metformin transporter 
Based on the primary localization of OCT2 in kidney, and as renal excretion is the major 
pathway for the elimination of xenobiotics, OCT2 plays an important role in detoxification. 
Among several drugs, OCT2 appears to be critical for disposition of metformin (42, 43). 
Numerous studies have been conducted to evaluate the relationship between OCT2 and the 
pharmacokinetics of metformin. Although the uptake of metformin was shown to depend on 
OCT1 function, Kimura et al., (44) claimed that metformin is a better substrate for OCT2 than 
for OCT1. Nonetheless, the role of OCT2 in metformin uptake is mostly associated with 
several genetic OCT2 variants such as A270S, M165I, R400C and K432Q which are 
nonsynonymous single nucleotide polymorphisms (SNPs) (42, 43). It was shown that 
metformin pharmacokinetics are deregulated in humans presenting these mutations. In 
addition, these mutations are ethnic-specific and the A270S variant represents the most 
important allele frequency for five ethnic populations including Caucasians, Afro-Americans, 
Asian-Americans, Mexicans and Pacific Islanders. M165I and R400C variants are present 
only in Afro-Americans and K432Q is present in both Afro-Americans and Mexicans (43). 
 
3.2.2. OCT2 role in Parkinson’s disease 
Parkinson’s disease is a neurological disorder which is characterized by loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNc) region of the brain (45, 46). In healthy 
individuals, normal functioning of dopaminergic neurons is maintained by a normal 
distribution of the dopamine transporter (DAT) whose role is to remove circulating dopamine 
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from presynaptic cleft in order to terminate neurological synapse (45, 46). However, Taubert 
et al., (47) reported an unexpected role of OCT2 in maintaining the healthy state of these 
neurons. They demonstrated that OCT2, besides of its role in secretion and removal of various 
cations in kidney, has a particular role in human brain where it localizes in SNc and where it 
colocalizes with DAT and tyrosine xydroxylase. In addition, OCT2 participates in the 
exclusive transport of two endogenous compounds, i.e., cyclo (his-pro) (CHP), and salsolinol 
(SAL). The first compound has a neuroprotective role by contributing to the maintenance of 
presynaptic transactions and by stimulating neuronal mitochondrial respiration. Inversely, 
SAL appears to act as a neurocytotoxic compound by inhibiting mitochondrial respiration and 
therefore by promoting oxidative stress (47). Moreover, OCT2 assures a strict balance in 
secreting CHP and SAL in such way that the ratio between the two is maintained with 
increased CHP levels. It was also demonstrated that the mutant OCT2 R400C loses the ability 
to transport CHP while maintaining SAL levels; moreover this switch may be detrimental for  
proper neuronal functioning and is therefore favorable for Parkinson’s disease development 
(47) 
 
3.2.3. OCT2 as transporter for anticancer drugs 
As mentioned above, cisplatin is one of the most effective antineoplastic agents used for 
treating a variety of solid tumors. In a study from Filipski et al., (48), it was shown that mice 
deleted in OCT1 and OCT2 severely abrogated urinary excretion of cisplatin, although plasma 
levels were not affected. Moreover, mice deficient in both OCTs was efficiently protected 
from cisplatin induced renal tubular damage. However, patients presenting OCT2 variant 
rs316019 were less affected from cisplatin cytotoxicity compared to reference OCT2. 
Therefore, the authors concluded that OCT2 possesses a critical role in renal toxicity induced 
by cisplatin (48). The role of OCT2 in cisplatin handling was also reported by Tanihara et 
al.,(49) and the authors also demonstrated the protective role of imatinib on renal 
nephrotoxicity caused by cisplatin. As mentioned above, OCT2 also participates in oxaliplatin 
and picoplatin uptake (30-32). 
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3.3. OCT3 
OCT3 (gene number SLC22A3) was independently identified in 1998 by two groups from 
Japan and Germany. Kekuda et al., (50) using two different expression systems, i.e., X. 
laevisoocyte and mammalian expression system (HeLa cells), reported that the newly 
identified protein was electrogenic cation transporter mainly expressed in fetal basal 
membrane of placenta and not in liver or kidney. Based on membrane localization, the authors 
reported that the main role of this transporter is to participate in the first line of defense against 
toxic xenobiotics. Data analysis also showed that interactions with OCT1 and OCT2 were 
negligible. OCT3 has the capacity to transport 1-MPP similarly to OCT1 and OCT2, but can 
also transport serotonin and desipramine (50). Transport of catecholamines occurs via two 
different systems: neuronal monoamine transporter (uptake1) and extra neuronal monoamine 
transporter (uptake2). The latter is characterized by the ability to transport catecholamines in 
an Na+ and Cl- independent manner as reported by Wu et al., (51). Moreover, the authors 
identified OCT3 as extra neuronal monoamine transporter (EMT) or uptake2 system. OCT3 
can transport various compounds such as amphetamine and methamphetamine, serotonin and 
dopamine. Thus, a role in handling of neuroactive compounds in the brain was exclusively 
attributed to OCT3 (51). A functional study from Gründemann et al., (52) using amino acid 
sequence analysis revealed that OCT3 is similar to OCTs and organic anion transporters 
(OATs) with respectively 50% and 30% homology. The protein is composed of 556 amino 
acids and contains 12 putative transmembrane domains. Gene localization was mapped to 
6q27 locus using fluorescence in situ hybridization (52). Regarding the distribution and the 
function of the organic cation transporters in the brain, both OCT2 and OCT3 are mainly 
expressed in cortex, thalamus, and hypothalamus. However, within these regions, OCT2 and 
OCT3 occupy different sub regions. Although both OCT2 and OCT3 are expressed in the 
central nervous system, OCT3 seems to be exclusively expressed in astrocytes that are 
localized in restricted areas (53). In the brain, OCT3 appears to perform a very important 
function by regulating osmotic pressure by salt ingestion (53). The exact mechanism by which 
OCT3 regulates the osmolarity is however unclear, but it is believed that it might participate in 
activation of secondary neuronal pathways responsible for insuring proper ways of 
neurotransmission which go through osmosensitive regions and other relay regions (53). 
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OCT3 is also believed to be strongly involved in stress, as it was labeled a corticosterone 
sensitive monoamine transporter. Moreover, in view of the fact that OCT3 has a high affinity 
for dopamine and its clearance, this transporter is strongly linked to sensitivity to 
psychostimulants and therefore to addiction behavior (53). These data suggest that brain 
transporters from the group of OCTs have a special role to play in drug transport and are 
targets for new drug development. 
3.3.1. OCT3 as transporter for anticancer drugs 
The role of OCT3 in the uptake of irinotecan, vincristine and melphalan was 
investigated by Shnitsar et al., (54). By stably transfecting Chinese hamster ovary (CHO) cells 
with human OCT3 cDNA and performing competition studies with (3) H]MPP (4-methyl-
pyridinium iodide and either melphalan, irinotecan or vincristine, the authors reported a 
significantly inhibited transport of (3) H]MPP (4-methyl-pyridinium iodide by these three 
agents suggesting the important role of OCT3 in handling of these antineoplastic compounds 
(54). 
3.4. OCTN1 
In 1997, Tamai et al., (55) cloned a cDNA corresponding to the novel organic cation 
transporter OCTN1 (gene number SLC22A4), which was then transiently expressed in 
HEK293T cells. The transfected cells were evaluated for transport capacity using the model 
organic cation transporter substrate TEA. The results showed that transport was saturable, 
energy dependent, and pH-sensitive. However, based on kinetic studies, OCTN1 exhibited a 
higher Michaelis-Menten constant compared to both OCT1 and OCT2, i.e. 440 µM vs 20 µM 
-100µM. Moreover, the authors revealed that OCTN1 operates in the apical membrane of 
renal epithelial cells. Because of the presence of a nucleotide binding motif, OCTN1 was 
suggested to act as an ATP-dependent transporter and it was shown that at pH 6.0 under ATP 
depletion, TEA transport was greatly decreased (55). Since OCTN1 is expressed in various 
human cell lines, Tamai et al., (55)  suggested that it may participate in the efflux of anti-
cancer drugs, although functional studies needed to be done in order to identify substrate 
specificity. A few years later, Gründemann et al., (56) expressed OCTN1 in HEK293T cells 
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and cells were assayed for transport of various substrates including TEA, carnitine, the anti-
oxidants ergothioneine, stachydrine (proline betaine) and betaine. Surprisingly, they reported 
that uptake of TEA and carnitine was negligible compared to that of ergothioneine, 
stachydrine and betaine and proposed OCTN1 be named ergothioneine transporter (ETT). 
However, despite their recommendation for the new appellation, both OCTN1 and ETT refer 
to gene number SLC22A4. Using RT-PCR, tissue distribution of OCTN1 was revealed to be 
highest in bone marrow and fetal liver (56). Consistent with other localization studies, OCTN1 
was reported to be specifically expressed in monocytes (CD14) and absent in stem and blast 
cells. Strong OCTN1 expression in small intestine and kidney was linked to its function in 
initial absorption and reabsorption of ergothioneine (56). Moreover, Gründemann et al., (57) 
reported that the newly proposed OCTN1 is not expressed in human liver, and to a very low 
extent in heart, muscle and skin. OCTN1 appears to be expressed in various species including 
rat and mouse. Despite the reported lower affinity of OCTN1 for carnitine, Pochini et al., (58) 
reported that structural analysis of OCTN1 binding pocket can fit substrates like acetyl 
carnitine and acetylcholine. However, when carnitine and ergothioneine are present, there 
seems to be a different structural organization of these molecules that prevents overlapping 
with the cation site, which explains the noncompetitive interaction with TEA. Regarding the 
transport of acetylcholine, Pochini et al., (58) also reported that human OCTN1 is involved in 
the bidirectional transport of this substrate. As epithelial cells of the small intestine and 
immune system cells such as lymphocytes participate in extra neuronal cholinergic transport, 
and since OCTN1 is predominantly expressed in these regions, it was suggested that this 
transporter may participate in catalysis of neo synthesized acetylcholine in order to activate 
receptor pathways in autocrine and paracrine mode (58). In heart, OCTN1 seems to play a role 
in absorption and removal of cations thereby modulating myocardial biogenesis (58) 
3.4.1. OCTN1 as transporter for anticancer drugs 
The role of OCTN1 in anticancer drug uptake was investigated by two groups. Okabe et al., 
(59) performed a screen with 60 cancer cell lines from the National Cancer Institute (NCI-60) 
for anticancer substrates. This revealed that DOX and mitoxanthrone, a close DOX relative, 
are substrates for OCTN1. Jong et al., (60) investigated the role of OCTN1 and OCTN2 in 
oxaliplatin uptake and cytotoxicity. Using HEK293T cells overexpressing OCTN1 and 
 31 
 
OCTN2 and primary dorsal root ganglion (DRG) neurons, data from this study showed an 
increased uptake and cytotoxicity of oxaliplatin in both model systems compared to mock. The 
authors also showed that uptake of ergothioneine (OCTN1) and carnitine (OCTN2) in 
HEK293T was decreased when competing with oxaliplatin, and as a consequence, the 
cytotoxicity was also reduced. In DRG neurons, the same effect was observed and the uptake 
was determined time, concentration, temperature and sodium dependent (60). 
3.5. OCTN2 
OCTN2 (gene number SLC22A5) was cloned from rat and human in 1998 by several groups 
including Sekine et al.,(61), Tamai et al., (62), and Wu et al., (63). OCTN2 is expressed in 
various tissues and organs including, among others, liver, kidney, small intestine, colon (64); 
skeletal muscle, lung (65); ovary, placenta and brain (66). OCTN2 is a high affinity sodium 
dependent carnitine transporter needed for the transport and oxidation of fatty acids in the 
mitochondria via a process known as β-oxidation (58), (67). Without carnitine, fatty acids 
cannot cross the mitochondrial inner membrane by the acyl carnitine translocase. Thus 
OCTN2, as a high affinity carnitine transporter, is abundantly expressed in various tissues, 
where it plays specific roles. For example, it was shown that in murine kidney, OCTN2 
regulates glomerular reabsorption of carnitine, some of which is excreted in urine due to its 
inability to bind to serum protein. Immunohistochemistry studies revealed that OCTN2 is 
localized to the apical membrane of proximal tubular epithelial cells. Transport of carnitine by 
OCTN2 in kidney is sodium dependent and seems to be linked to co-expression of PDZ 
domain-containing proteins such as PDZK1 protein at the apical membrane, although levels of 
OCTN2 expression do not seem to depend on PDZK1 expression (67). PDZ domains are 
protein modules that regulate multiple processes including transport and signaling (68). In the 
intestine, OCTN2 participates in intestinal absorption of carnitine, although its role in this 
process is still controversial (67). In addition, although significant levels of OCTN2 are 
detected in small intestine and colon, there is another nutrient transporter, PEPT1, which is 
strongly expressed in these organs. Similarly, to kidney, OCTN2-mediated transport of 
carnitine in the intestine seems to be regulated by PDZK1 protein. Human and murine in vitro 
studies showed that uptake of carnitine is saturable between 10 µM and 20 µM (67). In heart, 
 32 
 
carnitine plays an important role in preserving skeletal muscle and carnitine deficiency causes 
cardiomyopathy. OCTN2, which is expressed in the vascular endothelium, transports carnitine 
in sodium dependent manner (67). The precise localization of OCTN2 in the vascular 
endothelium was also suggested to indicate a role in carnitine accumulation in heart. OCTN2 
is also expressed in liver where carnitine biosynthesis occurs. Tamai et al., (67) reported 
strong expression in liver of gamma-butyrobetaine dioxygenase which catalyzes carnitine 
production from gamma-butyrobetaine. In fact, OCTN2 can transport gamma-butyrobetaine in 
a sodium dependent manner with Km of 13 µM, although the real contribution of gamma-
butyric transport comes from another transporter, i.e., GAT2 (67). Yet, based on studies using 
mutated OCTN2 in mice, it appears that GAT2 gamma-butyrobetaine transport prevails only 
when OCTN2 does not perform its function and GAT2 only transports gamma-butyrobetaine 
acid into the liver, where carnitine biosynthesis occurs, to supply other tissues with carnitine 
(67). OCTN2 is also expressed in brain capillary endothelial cells and this correlates with 
regulatory transport of carnitine across the blood-brain barrier. Studies have revealed that the 
precise localization of OCTN2 is on the brain side and not on blood side suggesting that 
OCTN2 might only participate in one directional transport of carnitine and acetyl carnitine 
from the blood to the brain (67). Moreover, OCTN2 is highly involved in carnitine and acetyl 
carnitine circulation in placenta. Lahjouji et al., (69) showed that OCTN2 is localized in the 
brush border membrane of placenta and is involved in carnitine transport in a sodium-, pH-, 
temperature- and osmolarity-dependent manner. They also reported that carnitine transport in 
placenta, mediated by OCTN2, is saturable at 11 µM which appears to be similar to the 
transport observed in kidney. Moreover, while in competition with TEA, valspodar and 
valproate, carnitine uptake is greatly inhibited suggesting that these substrates are specific for 
OCTN2 as well. However, in the case of verapamil, it seems that inhibition of OCTN2 is 
triggered by both competitive and noncompetitive modes (69). The implication of other 
carnitine transporters has not yet been excluded. In fact, OCTN1 is also expressed in placenta 
and transports carnitine in a sodium-dependent manner although the affinity of OCTN1 for 
carnitine has not been reported. A study from Maekawa et al., (70) has identified cartregulin 
which is homologous to OCTN2 in rat brain and acts by stabilizing the mRNA of OCTN2. 
Moreover, a novel gene encoding full length of OCTN2 was identified with the addition of 24 
amino acids in the first extracellular loop. This variant, named OCTN2 N2VT, exhibited 
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several different features compared to wild type OCTN2 including reduced glycosylation 
which regulated retention of OCTN2 N2VT in the reticulum endoplasmic compared to normal 
glycosylation and subsequent expression on the cell surface. It was also found that while 
OCTN2 N2VT is expressed in HeLa cells, carnitine uptake is severely abrogated due to lack 
of expression on the cell surface (70). 
3.5.1. OCTN2 as transporter for anticancer drugs 
As mentioned above, OCTN2 plays a role in oxaliplatin uptake (60). Moreover, Hu et al., (71) 
reported a role of OCTN2 in the uptake of the topoisomerase II poison etoposide. The study 
was performed in cells expressing either human or mouse OCT2 challenged with both 
carnitine and etoposide. The results showed a marked decrease in carnitine transport 
suggesting the important role of OCTN2. However, the authors were able to reverse the 
inhibition by adding carnitine in excess. 
  
3.6. OCTN3 
OCTN3 is another member of the SLC22 family that has not received much attention. Duran 
et al., (72) successfully isolated mOCTN3 cDNA from small intestine. Moreover, using 
commercially available antibodies against OCTN2 and OCTN3, the authors also reported that 
OCTN3 localizes on the basolateral membrane of the enterocytes in rat and chicken small 
intestine compared to OCTN2 which is localized on the apical membrane. OCTN3 was also 
found to be responsible for carnitine uptake in the peroxisome in mammals. Using a specific 
antibody 629 that binds to mouse OCTN3, Lamhonwah, et al., (73) localized OCTN3 on the 
peroxisomes and the cisternae of the rough reticulum endoplasmic. As already pointed out, 
carnitine is essential for β-oxidation in mitochondria, but is also important for β-oxidation in 
the peroxisome. The role of carnitine in the peroxisome is to shuttle short-sided hexacosanoid 
acid and pristanic acid which are products of β-oxidation in the peroxisome and exports them 
into the mitochondria as carnitine esters (73). The evidence for the existence of carnitine 
acyltransferases and carnitine translocase in the peroxisome further supports the importance of 
carnitine transport to this organelle. mOCTN3 transports carnitine in the peroxisome with 
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affinity of 20µM (73). The authors, based on comparison with mOCTN3, have also predicted 
that, similarly to OCTN1 and OCTN2 which are mapped at 5q31 locus, OCTN3 may also be 
localized at the same region in humans and may play an important role in carnitine 
homeostasis. They also predicted that if OCTN3 is mutated, this should confer susceptibility 
to several diseases related to OCTNs such as Crohn’s disease (73). 
3.7. CT2 (OCT6) 
OCT6 or CT2, for carnitine transporter 2 (gene number SLC22A16), has been expressed in 
Xenopus laevis followed by characterization of the corresponding protein by Enomoto et al., 
(74). Structural analysis studies performed by the authors allowed to identify a CT2 cDNA 
encoding 543 amino acid protein that shared up to 40% identity with the other carnitine 
transporter members such as OCTN1 and OCTN2 (reported to be CT1 for carnitine transporter 
1). Carnitine transport was found to be saturable at 50 µM and the affinity for this substrate 
was evaluated to 20 µM. It was shown that uptake of carnitine is not entirely sodium 
dependent. Competition studies with other carnitine derivatives and betaine greatly inhibited 
CT2, but not choline and other selected substrates. Tissue distribution analysis revealed that 
CT2 is expressed in human testis, and not in any other tissues including brain, placenta, heart, 
ovary, small intestine, and colon (74). Nonetheless Sato et al., (75) found that CT2 was 
strongly expressed in normal human endometrium and that this expression was regulated by 
progesterone. Analysis of CT2 gene also revealed that there were no identical sequences in the 
5’ regions upstream of progesterone responsive elements suggesting that, in endometrial 
cancer, CT2 expression should not depend on progesterone (75). In another study, Okabe et 
al., (76) characterized CT2 from normal vs tissues from patients with acute leukemia and 
reported that CT2 is predominantly expressed in bone marrow and testis and that high levels 
of CT2 are observed in fetal liver, but not in normal liver (76). Moreover, CT2 is expressed in 
a variety of leukemia and its expression is tightly related to hematopoiesis. CT2 was reported 
to transport typical OCTs substrates such as TEA (76). CT2 seems to have an important role in 
lung cancer and Kunii et al., (77)  reported that its expression correlates with cisplatin uptake. 
The authors also reported that OCT2 is not in fact the main platinum drug uptake transporter, 
but is more likely to be CT2 (OCT6). Studies from our laboratory involving the role of CT2 
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have demonstrated that this protein is involved in the transport of the anti-cancer polyamine 
analogue Bleomycin- A5 (78). Bleomycin is currently used as antineoplastic agent for treating 
various cancers such as lymphomas and carcinomas. By overexpressing CT2 in various cancer 
cell lines, Aouida et al., (78) showed that these cells are extremely sensitive to Bleomycin- A5 
compared to control cells. The results correlated with the previously shown increased uptake 
of polyamines mediated by Agp2 which is a high affinity carnitine transporter in 
Saccharomyces cerevisiae (79). 
3.7.1. CT2 as anthracycline transporter 
By injecting CT2 cRNA in Xenopus oocytes and stably transfecting Jurkat cells, Okabe et al., 
(76) tested the behavior of this transporter towards DOX. The authors reported that transport 
of DOX was saturable, dose dependent and uptake was independent of sodium with apparent 
affinity constant of 5 µM. A slight decrease in cell viability in control cells vs ones 
overexpressing CT2 was observed. Nonetheless, it was claimed that CT2 is a DOX importer. 
In a study involving the role of CT2 in human epithelial ovarian cancer, Ota et al., (80) 
reported that CT2 transports DOX in clear cell adenocarcinoma cell lines. Data from this study 
suggested that anthracyclines might be used in combination chemotherapy with paclitaxel and 
other platinum drugs used in ovarian cancer. Moreover, they predicted that clear cell 
adenocarcinoma expressing CT2 might display a better response to combinational treatment 
with platinum drugs and anthracyclines compared to other ovarian cancer cell lines (80). 
Correlation between CT2 expression and anthracyclines action was reported by Lal et al., (81) 
in a study investigating the genetic variants of this transporter versus DOX and its metabolite 
doxorubicinol in Asian breast cancer patients. Moreover, by studying different ethnic groups, 
the authors revealed that CT2 presented at least four different polymorphisms. Comparison 
between Asian and Caucasian groups showed differences in allele and genotype frequencies 
and data suggested that CT2 variations present the hallmark of DOX sensitivity and even other 
drugs candidates. CT2 c.146G allele was reported to harbor increased exposure levels to DOX 
and its metabolite doxorubicinol and has, as a consequence, shown better outcome of cancer 
treatment (81). 
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Figure 4. Schematic representation of the OCTs and OCTNs transporters localization in liver 
(hepatocytes), kidney (proximal tubule cells) and blood-brain barrier (brain endothelial cells). 
OC+- organic cations. Adapted from (20). 
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Table 1. SLC22 organic cations/carnitine transporters. Adapted from (20, 21, 82) 
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4. Organic anion transporters 
Organic anion transporters (OATs) include more than ten transporter members (figure 4) and 
are part of the SLC22 subfamily of transporters (83). Localized on almost all epithelial 
physiological barriers, OATs are involved in the transport of numerous anionic compounds. 
OATs are mostly facilitator transporters, but it was shown that anionic substrates are also 
imported with counter transport of α-ketoglutarate. Thus, OATs that operate by such 
mechanism form part of a rate-limiting «tertiary» transport system as transport is driven by 
concentration gradient created from the sodium-decarboxylate cotransporter (NaDC3) and 
Na+, K+, ATPase (83). The first cloned OAT was the novel kidney transporter (NKT) which 
was designated OAT1 (SLC22A6). It was demonstrated that the hippuric acid derivative, the 
p-aminohippuric acid (PAH) is a typical OAT substrate. Moreover, OATs have the ability to 
transport xenobiotics such as antibiotics, antivirals, anti-inflammatory drugs, diuretics, and 
non-steroidals (83). A study conducted by Ahn et al., (84) demonstrated that typical OCT 
substrates can interact with OATs, specifically with mOAT1, mOAT3 and mOAT6. These 
substrates include TEA, 1-MPP, cimetidine, metformin, verapamil procainamide, clonidine 
and others. Moreover, some of these substrates appear to be member specific as procainamide, 
clonidine and metoclopramide can bind to mOAT3, but not to mOAT6. It was also 
demonstrated that 1-MPP can bind to mOAT1 and mOAT6 although with low affinity (Km of 
~1mM and ~2mM). The authors also reported that the assayed cationic substrates have the 
ability to equally inhibit the cationic transport system (N1- methyl nicotinamide) and the 
anionic transport system (PAH) (84). 
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Table 2. SLC22 organic anion transporters. Adapted from (83) 
 
N/D- not documented 
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Figure 5. Schematic representation of the OATs and OATPs transporters localization in liver 
(hepatocytes), kidney (proximal tubule cells) and blood-brain barrier (brain endothelial cells). 
Adapted from (20, 83, 85). 
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5. Hypothesis and Objectives 
As discussed above in the Introduction and despite numerous studies aimed at investigating 
the role of OCTs transporters in the uptake of various anticancer agents including 
anthracyclines, the implication of these transporters in anthracyclines uptake has yet not been 
clearly demonstrated. It is noteworthy that anthracyclines are still believed to undergo cellular 
penetration by passive diffusion and cellular transport of the anthracycline DOX by facilitated 
transport exerted by CT2 was only demonstrated by Okabe et al., (76). However, as the 
authors only showed a slight decrease in cell viability in cells overexpressing CT2 protein 
compared to control, and as down regulation of CT2 was never done, the role of this 
transporter in anthracyclines transport remains highly inconclusive. We propose that the 
anthracycline DNR, a close relative to DOX, enters cells by means of facilitated transport 
mechanism mediated specifically by OCT1. Thus, screening of patients currently treated with 
anthracyclines, for OCT1 status might constitute a useful predictor of responsiveness towards 
DNR. 
In view of these considerations, our general objective is to demonstrate that OCT1 is the 
specific transporter for DNR and we intend to accomplish this by: 
 Evaluating DNR accumulation in various cell lines 
 Evaluating OCT1 expression in various cell lines 
 Performing competition studies with DNR and key OCTs substrates  
 Downregulating OCT1 and subsequent evaluation of DNR transport 
 Overexpressing OCT1 and subsequent evaluation of DNR transport 
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Background: Anthracyclines are antitumor agents used for treating various cancers.  
Results: Human OCT1 displayed a high affinity for the uptake of the anthracycline 
daunorubicin.  Downregulation of OCT1 blocked the uptake of daunorubicin and conferred 
cellular resistance to the drug.   
Conclusion: Human OCT1 possesses the ability to transport anthracyclines into cancer cells. 
Significance: Defects in OCT1 function are likely to cause drug resistance. 
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ABSTRACT 
Anthracyclines such as daunorubicin are anticancer agents that are transported into cells, and 
exert cytotoxicity by blocking DNA metabolism.  Although there is evidence for active uptake of 
anthracyclines into cells, the specific transporter involved in this process has not been identified.  
Using the high-grade serous ovarian cancer cell line TOV2223G, we show that OCT1 mediated 
the high affinity (Km ~ 5 μM) uptake of daunorubicin into the cells, and that micromolar amounts 
of choline completely abolished the drug entry.  OCT1 downregulation by shRNA impaired 
daunorubicin uptake into the TOV2223G cells, and these cells were significantly more resistant 
to the drug in comparison to the control shRNA.  Transfection of HEK293T cells, which 
accommodated the ectopic expression of OCT1, with a plasmid expressing OCT1-EYFP showed 
that the transporter was predominantly localized to the plasma membrane.  These transfected 
cells exhibited an increase in the uptake of daunorubicin in comparison to control cells 
transfected with an empty EYFP vector.  Furthermore, a variant of OCT1, OCT1-D474C-EYFP, 
failed to enhance daunorubicin uptake.  This is the first report demonstrating that human OCT1 
is involved in the high affinity transport of anthracyclines.  We postulate that OCT1 defects may 
contribute to the resistance of cancer cells treated with anthracyclines. 
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INTRODUCTION 
Members of the anthracycline family such as doxorubicin (DOX) and daunorubicin (DNR) are 
hydrophilic anticancer agents that are transported into cells where they intercalate into the DNA, 
disrupt the function of DNA polymerase, and promote cell death (86).  Anthracyclines exhibit 
high tissue-penetration and retention in nucleated cells, and are used for treating a variety of 
cancers that include leukemia and lymphomas, as well as breast, lung, ovarian, gastric and 
thyroid cancers (87).  However, a significant fraction of these cancer types is resistant to 
anthracyclines.  Notably, over 50 % of older patients (> 60 yrs) with acute myeloid leukemia 
(AML) do not achieve complete remission after induction chemotherapy with DNR, and in some 
cases, remission is short-lived due to drug resistance (88-90).   
A characteristic mechanism associated with drug resistance is the elevated levels of plasma 
membrane ABC transporters (91).  These include the multidrug resistant efflux pump, 
MDR1/ABCB1, and the multidrug resistant-associated protein, MRP1, which are known to 
increase efflux of chemotherapeutic agents, allowing tumor (and normal) cells to evade drug-
induced cytotoxicity (91, 92).  Drug efflux transporters are known to be upregulated in some 
AML patients, and there is evidence suggesting that ABCB1 can expel DNR from the cells (93).  
However, inhibition of ABCB1 with valspodar did not improve outcomes for/treatment in drug-
resistant AML patients (93).  This suggests that other alternative mechanisms are involved in 
anthracycline resistance.  These mechanisms are likely to involve (i) defects in DNR entry into 
cancer cells via uptake transporter(s), (ii) enhanced sequestration of DNR by lysosomes for 
detoxification and (iii) increased repair of DNR-induced DNA lesions.  To date, the uptake 
transporter allowing entry of DNR into cells has not been identified (76).  Such a transporter 
could represent a critical pathway that, when defective, leads to drug refractory disease.   
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Human cells possess three high affinity (OCTN1/SLC22A4, OCTN2/SLC22A5 and 
hCT2/SLC22A16), as well as three low affinity (OCT1/SLC22A1, OCT2/SLC22A2 and 
OCT3/SLC22A3) L-carnitine transporters (21).  These are versatile organic cation transporters 
that possess varying affinities for a range of substrates, including several anticancer drugs such 
as bleomycin and oxaliplatin (31, 78).  Okabe et al (2005) initially reported that hCT2 has the 
ability to transport DOX, although the evidence remains circumstantial (76).  In their study, the 
authors injected hCT2 cRNA into the oocytes of Xenopus laevis and determined a high affinity 
for the uptake of DOX with an apparent Km of 5.2 μM (76).  However, the characterization of 
hCT2 as a DOX-transporter was limited as competition assays were not performed with the 
known substrate L-carnitine and knockdown of hCT2 expression was not analyzed for effects on 
anthracycline resistance.  It is noteworthy that the authors examined a few paraffin embedded 
samples derived from AML patients who were either responsive or unresponsive to 
anthracyclines in order to determine whether a correlation exists with hCT2 gene expression 
level, but the results were inconclusive (76).  We subsequently discovered that hCT2 is involved 
in the uptake of the anticancer drug bleomycin, using cancer cell lines that either expressed or 
did not express hCT2 (78, 94, 95).  Moreover, we demonstrated that L-carnitine can effectively 
block bleomycin uptake and protect cancer cells expressing hCT2 from the genotoxic effects of 
the drug (78).  In addition to hCT2, OCT1 is another organic cation transporter involved in the 
uptake of anticancer agents such as platinum drugs (31, 96).  OCT1 has also been implicated in 
the transport of the anti-diabetic drug metformin, underscoring the wide range of substrate 
recognition by these organic cation transporters (97).  Together with the work by Okabe et al 
(2005) and the above findings, it appears that one or more transporter(s) may be involved in the 
uptake of anthracyclines into cells.  
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In this study, we used the high-grade serous ovarian cancer cell line TOV2223G and show for 
the first time that OCT1 is a high affinity transporter for DNR.  Uptake of DNR was effectively 
blocked by low concentrations of choline, which was previously reported to be a high affinity 
substrate for OCT1 (98).  We also show that shRNA knockdown of OCT1 significantly 
diminished the expression of the transporter as determined by Western blot analysis probed with 
anti-OCT1 antibody and greatly reduced DNR uptake in TOV2223G cells.  Downregulation of 
OCT1 enhanced the resistance of these cells to DNR.  In support of these observations, 
expression of OCT1 as an EYFP fusion protein, OCT1-EYFP, revealed that the primary cellular 
localization of the transporter is on the plasma membrane.  These OCT1-EYFP expressing cells 
increased the uptake of DNR.  Collectively, our findings provide compelling evidence that 
suggests OCT1 functional levels may have a vital role in modulating the response to 
chemotherapy with anthracyclines.  
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RESULTS 
DNR accumulates in several cancer cell lines in a time- and concentration-dependent 
manner—Once suitable assay conditions were established (see Materials and Methods), DNR 
(see chemical structure in Fig. 1A) uptake into cancer cell lines was monitored by three 
independent methods using either (i) FACS, (ii) a fluorometric microplate reader equipped with a 
tandem filter set with excitation at 544 nm and emission at 590 nm, or (iii) an epifluorescent 
microscope.  We analyzed DNR uptake in five cell lines that included two of ovarian cancer 
(TOV2223G and OV866(2)), one of embryonic kidney (HEK293T), and two of leukemia (K562 
and HL60).  We monitored DNR uptake when the concentration was fixed at 5 µM, a 
concentration that was used in a study involving ceramide potentiating multidrug resistance (99) 
and, in particular, since it was near the estimated concentration of 4 µM given to cancer patients 
(100).  Each of these cancer cell lines showed a different rate of uptake of DNR with K562 
showing the highest level when the concentration was fixed at 5 µM as demonstrated by FACS 
or fluorometric analysis (Fig. 1B and 1C, respectively).  In addition, DNR entered TOV2223G 
and HL60 cells in a concentration-dependent manner, with nearly 2-fold more drug accumulating 
in the TOV2223G cells (Fig. 1D).  These data indicate that DNR uptake cannot be by diffusion, 
otherwise each cell line examined would show the same level of drug uptake (see discussion).  
Instead, our data suggest that there is an active process to mediate the entry of the drug into these 
cell lines, which could vary between cell lines.   
In parallel, these cells were examined by epifluorescent microscopy which revealed that DNR 
entered and accumulated in the nucleus (Fig. 1E, and Supplemental data Fig. S1), consistent with 
the action of the drug in damaging DNA (86).  Accumulation of the drug was not influenced by 
the cell size as the drug does not stain the cytoplasm, and in addition TOV2223G is significantly 
 49 
 
larger that K562, which showed the highest level of DNR accumulation.  All three methods 
showed similar results for DNR uptake in a given cell type, although quantitative assessment was 
achieved by FACS or the fluoro spectrometer.     
 
A high-affinity transporter mediates DNR uptake in TOV2223G cells—We selected 
TOV2223G cells as the model cancer cell line (Fig. 1B) to determine whether DNR transport 
would be mediated by a low or high affinity transporter.   We chose to study the TOV2223G cell 
line as it showed an intermediate uptake and responded to DNR toxicity (see below), as well as 
the fact that ovarian cancer patients are also treated with anthracyclines.  Kinetic analysis 
showed that DNR uptake was saturable at ~ 15 μM (Vmax of 29 + 0.41 pmol/2 x 104/min) with an 
apparent Km of 3.0 + 0.4 μM (Fig. 2).  Comparable to the kinetic values reported for L-carnitine 
transport by the high affinity L-carnitine transporter hCT2 (101), these results indicate that there 
exists at least one high affinity component for DNR transport into TOV2223G cells, again 
countering previous arguments that DNR diffuses into cells.  Similar kinetics were observed with 
HEK293T or HL60 cells, yielding apparent Km of ~ 5 μM, suggesting that the high affinity DNR 
transporter also exits in these cancer cell lines.  As such, we conducted all subsequent 
experiments with low concentrations (5 μM) of DNR.  In a similar manner, we measured the 
kinetics for the uptake of another anthracycline, DOX.  DOX uptake was also saturable with an 
apparent Km of 10 + 3 μM, suggesting that DNR is a better substrate than DOX for the 
transporter.  In addition, DNR or DOX uptake was not influenced by changes in the pH ranging 
between 6.5 to 8.0.   
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The organic cation transporters hCT2, OCTN1 and OCTN2 are not involved in DNR 
uptake—hCT2 and OCTN2 have been discovered as high affinity transporters for L-carnitine, 
while OCTN1 is reported to be a low affinity transporter for this substrate (21, 56, 62, 101, 102).  
Subsequent studies by Okabe et al., raised the possibility that hCT2 and OCTN1 could be 
transporters for DOX, although no direct experiments were performed to test these assertions 
(59, 76).  To determine whether any of these three organic cation transporters are involved in 
DNR uptake, we examined whether the known substrates for these transporters could compete 
for the drug uptake.  Briefly, a fixed concentration of DNR (5 µM) was added together with a 
200-fold excess of L-carnitine (1 mM) to cultures of the TOV2223G and OV866(2) cells 
preincubated in uptake buffer.  As shown in Fig. 3, L-carnitine did not block the uptake of DNR 
into either of the ovarian cancer cell lines (see also Supplemental data Fig. S2).  If indeed hCT2 
and OCTN1 were involved in DNR uptake, as previously implicated, we would expect that the 
excess of L-carnitine to at least cause a significant reduction in DNR uptake.  These results 
indicate that the presence of excess L-carnitine does not affect DNR uptake, suggesting that the 
three transporters OCTN1, OCTN2 and hCT2 do not mediate DNR uptake.  Progesterone, which 
has been shown to induce hCT2 expression by several fold (75), did not cause an influx of DNR 
when cells were pre-cultured in the presence of the hormone for 3 h (Fig. 3D). This is consistent 
with the above observation that hCT2 does not have a major role in the uptake of DNR.  
Since many transporters are known to be Na+-dependent or -independent, we examined if 
omission of NaCl from the uptake buffer would alter DNR uptake in cells.  Replacing NaCl with 
N-methyl-D-glucamine that maintains the ionic strength in the uptake buffer did not affect DNR 
entry into cells (Fig. 3E), suggesting that transport of DNR into the cells is not coupled with the 
movement of Na+ ions.    
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Choline effectively blocks DNR uptake—We next examined whether the OCT family members 
of polyspecific organic cation transporters would be involved in mediating DNR uptake.  OCT1, 
2 and 3 are reported to have different affinities for a wide range of cationic substrates that 
include choline, ergothioneine, phenformin (a structurally related form of metformin), thiamine 
and polyamines (23, 98, 103).  Incubation of the TOV2223G cells with DNR together with the 
indicated cationic substrate, revealed that choline effectively competed with DNR for uptake, 
whereas ergothioneine (100 µM), phenformin (50 µM), and thiamine (50 µM), partially (p < 
0.01) inhibited DNR uptake at the concentrations used (Fig. 3 F and G and Fig. 4, respectively).  
In contrast, a high concentration (1 mM) of polyamine spermidine (SPD) had only a modest 
effect on the uptake of DNR (Fig. 4). This is consistent with OCT transporters that function as 
low affinity permeases for polyamines (104).  Since choline is a potent competitor in DNR 
uptake and OCT1 has been previously described as a high affinity transporter of choline, our 
results suggest that OCT1 may play a role in the high affinity uptake of DNR.    
 
shRNA-OCT1 knockdown in TOV2223G cells reduces DNR uptake and enhances  
resistance to the drug—It has been shown that OCT1 is expressed predominantly in the liver, 
the organ that metabolizes DNR, whereas expression levels of OCT2 and OCT3 are not 
detected(20).  To test the hypothesis that OCT1 is a DNR transporter, we designed two shRNA 
constructs to specifically downregulate the transporter in the TOV2223G cells.  These constructs 
targeted the 5`-untranslated and the C-terminus of the mRNA sequence of the OCT1 gene.  
Stable clones carrying the shRNA construct against the 5`-untranslated region was effective in 
down-regulating OCT1 expression levels by more than 95% when compared to the control 
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shRNA LMP vector, as determined by immunoblot analysis probed with polyclonal antibody 
against OCT1 and quantified by Image J (Fig. 5A).  The shRNA construct against the C-terminus 
of OCT1 had no effect in downregulating OCT1 expression (data not shown).  Consistent with 
the downregulation of OCT1, fluorometric analysis revealed that DNR uptake was significantly 
reduced (3- to 5-fold) in the shRNA-OCT1 knockdown cells compared to cells carrying the 
control shRNA (Fig. 5B).  The low level of DNR uptake observed with the shRNA-OCT1 
knockdown cells demonstrates that downregulation by shRNA-OCT1 was not sufficient to 
abolish DNR transport or that gene knockdown was incomplete, although other redundant 
transporter may exist to mediate DNR uptake.  In a parallel experiment, epifluorescent 
microscopy showed that the accumulation of DNR was nearly undetectable in the shRNA-OCT1 
knockdown cells compared to the shRNA LMP vector control cells (Fig. 5C).  There was no 
difference in DNR uptake between the shRNA LMP vector control and the TOV2223G cells 
alone (data not shown), suggesting that the slightly higher OCT1 protein level detected in the 
LMP vector control vs the TOV2223G cells could be due to susceptibility to extraction (Fig. 
5A).  In another control experiment, the uptake of rhodamine was not altered in the shRNA-
OCT1 knockdown cells compared to the shRNA control cells (see also below).  These results 
strongly support a role for OCT1 in mediating DNR uptake into TOV2223G cells.   
To investigate the effect of OCT1 knockdown with respect to cell sensitivity to DNR, we 
performed a viability assay to monitor surviving cells, following exposure to the drug for 72 
hours.  Under these conditions, the normal TOV2223G cells carrying the LMP vector showed a 
survival of nearly 40% (Fig. 5D).  However, OCT1 knockdown TOV2223G cells were protected 
from DNR toxicity and showing nearly 100 % survival (Fig. 5D).  This finding strongly supports 
 53 
 
a role for OCT1 in the transport of DNR, and excluding any possibility of drug diffusion into the 
cells.            
 
OCT1-EYFP overexpression enhances DNR uptake in HEK293T cells—To determine 
whether OCT1 overexpression could enhance DNR uptake in cells, we designed an expression 
system to drive OCT1 expression as a OCT1-EYFP fusion protein in the vector pEYFP-N1 
(105).  Transient transfection with pOCT1-EYFP into the TOV2223G cell line yielded very few 
cells that expressed the OCT1-EYFP fusion protein (< 1 % in the transfected population).  
Therefore, we used HEK293T cells as an alternative host cell since it was reported to 
accommodate the expression of plasma membrane transporters (23, 106).  At least 5 to 10 % of 
the pOCT1-EYFP transfected HEK293T cells expressed the OCT-1 EYFP fusion protein.  
Epifluorescent microscopy revealed that the OCT1-EYFP protein was specifically present on the 
plasma membrane, consistent with a previous report that used immunopurified antibodies against 
OCT1 (23, 106), while the EYFP alone showed non-specific cellular localization (Fig. 6A).  
Because HEK293T cells can accommodate the ectopic expression of the OCT1-EYFP fusion 
protein, we monitored the uptake level of DNR into these cells.  After 24 hours of transient 
transfection of HEK293T cells with the empty pEYFP-N1 vector or the pOCT1-EYFP plasmid, 
the cells were preincubated in uptake buffer followed by the addition of DNR (5 µM) for 1 hour 
and uptake was determined by FACS analysis only in the fraction of EYFP expressing cells (see 
Materials and Methods).  The OCT1-EYFP expressing cells showed nearly 50 % increase in 
DNR uptake, compared to the cells that were transfected with the empty vector alone (Fig. 6B).  
In contrast, OCT1-EYFP expression did not stimulate rhodamine uptake in HEK293T cells (Fig. 
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6C).  These findings show that the expression of OCT1-EYFP fusion protein correlates with 
enhanced DNR uptake, and strongly reinforces the role of OCT1 as a transporter of DNR. 
 
The variant OCT1-D474C-EYFP is unable to increase DNR uptake in HEK293T cells—
Molecular models have predicted that the transmembrane helix domain 11 of the rat OCT1 is 
involved in substrate binding (107).  Several mutations have been created in this region of the rat 
OCT1 gene (107).  In particular, the replacement of Asp475 with cysteine resulted in nearly 
complete  reduction (98%) of the transport of the model substrate tetraethylammonium in 
oocytes expressing the rOCT1-Asp475Cys variant (107).  The same mutation was created in the 
OCT1-EYFP construct by site-directed mutagenesis; Asp474, which corresponded to the amino 
acid residue of the human OCT1, was substituted with cysteine generating the variant OCT1-
D474C-EYFP.  Transient expression of this variant in HEK293T cells demonstrated its 
localization to the plasma membrane (Supplemental data Fig. S4).  However, this OCT1-D474C 
variant did not enhance DNR uptake in HEK293T cells, as observed with the native OCT1-
EYFP construct (Fig. 6B).  We conclude that the transport function of OCT1 is required for the 
uptake of DNR and exclude the possibility that OCT1 might act via another transporter through 
protein-protein interaction.   
 
High levels of OCT1 mRNA correlates with increased survival in patients with high-grade 
serous epithelial ovarian cancer—To explore the potential significance of OCT1 in the context 
of chemotherapy, we used the Affymetrix gene expression to analyze 469 cases of high-grade 
serous epithelial ovarian cancer from The Cancer Genome Atlas (TCGA) dataset (108).  The 
dataset represented patients in different stages of the cancer and were treated with a combination 
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chemotherapy that included platinum and taxol reagents.  Using the online tool Kaplan-Meier 
Plotter (109, 110), we observed that patients with a high level of OCT1 mRNA have 
significantly better overall survival (p = 0.013) than those with low expression levels of this gene 
(Fig. 7).  This difference accounts for an average of 10 months increased life expectancy for 
patients with higher OCT1 expression levels (Fig. 7).  Since OCT1 has the ability to transport 
derivatives of cisplatin, as well as paclitaxel (31, 35), it is possible that ovarian cancer patients 
expressing reduced levels of OCT1 are associated with poor outcome following chemotherapy. 
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DISCUSSION 
In this study, we demonstrate that the human organic cation transporter OCT1 is involved in the 
high affinity transport of DNR, a member of the anthracycline family of anticancer drugs.  This 
conclusion was derived from the following findings: (i) several cell lines displayed saturable 
transport of DNR; (ii) the kinetics for DNR transport is comparable for the uptake of the model 
substrate tetraethylammonium and the neurotoxin methyl-4-phenylpyridinium with apparent Km 
ranging between 5 to 50 µM by HEK293 cells designed to express the human OCT1 (107, 111); 
(iii) the rate of DNR uptake varies between cell lines and may be dependent upon the expression 
level of the OCT1 transporter (see Supplemental data Fig. S3); (iv) choline at low concentrations 
effectively competed with DNR uptake, underscoring the participation of a high affinity choline 
uptake system in the transport of DNR; (v) downregulation of OCT1 reduced the transport of 
DNR into the cancer cell line TOV2223G, as well as causing DNR resistance; and (vi) 
expression of OCT1 as an EYFP fusion protein revealed that it is localized to the plasma 
membrane consistent with a previous report (23, 106), and enhanced the uptake of DNR, but not 
rhodamine.  In this latter finding, not all of the expressed OCT1-EYFP protein might be 
functionally active to yield substantially higher level of DNR uptake.  The overexpression of 
OCT1-EYFP might displace resident plasma membrane protein that could have adverse effects 
on the functioning of the transporter such as causing the eviction of accessory proteins that are 
necessary for the proper transport function of OCT1 (112).   On the basis of our findings, we 
exclude the possibility that DNR uptake can be explained by the drug diffusing into the cells.  In 
fact, there is growing evidence precluding a diffusion process by which DNR enters into cells.  
An earlier study demonstrated that DOX can penetrate artificial membranes, but it cannot readily 
go through natural membranes (113).  Moreover, yeast cells lacking the plasma membrane 
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regular Agp2 that controls the expression of the uptake transporters Sam3 and Dur3 do not take 
up DOX (114).  Uptake of DOX into the agp2Δ mutant can be rescued by the expression of 
either of the active transporters Sam3 or Dur3, which provides strong support for transporter-
mediated uptake of anthracyclines into cells as the principal process (114).         
In the OCT family of transporters, OCT1 shares 75 and 50 % identity at the amino acid level 
with OCT2 and OCT3, respectively.  We propose that OCT1 has a major role as a transporter for 
anthracyclines.  The deletion of the OCT1 gene in mice caused significant upregulation of OCT2 
and OCT3 (23, 98, 103), suggesting that if a similar mechanism occurs with OCT1-shRNA 
downregulation in human cells then these two later transporters are unlikely to be involved in 
DNR uptake since they cannot compensate for OCT1 role in the drug uptake.  Notwithstanding, 
we have not directly tested whether OCT2 and OCT3 could perform a role in DNR transport.  
While these three transporters share the ability to transport metformin and the model substrate 
tetraethylammonium, they also mediate the uptake of distinct substrates (23, 106).  OCT2 has 
been shown to transport platinum anticancer drugs and both OCT2 and OCT3 secrete small 
organic cations in the kidney and placenta.  OCT2 and OCT3 also play important roles in the 
brain by transporting neurostimulants such as dopamine, corticosterone, amphetamine and 
methamphetamine (20, 53).  Thus, these two transporters have an important role in the 
neurological response to psychostimulants, and their expression is strongly linked to addiction 
behavior (20, 115).  Since anthracyclines undergo metabolism in the liver where OCT1 is 
expressed, as well as OCT3, but not OCT2 (116), raises the possibility that at least OCT2 may 
not be involved in the uptake of anthracyclines and that substrate specificity may be governed by 
the site of action.  Thus, the residual level of DNR uptake in the TOV2223G cells knockdown 
for OCT1 could be accounted for if there is at least one other DNR transporter.     
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OCT1 also shares nearly 30% identity at the amino acid level with transporters that belong to the 
OCTN family, which include OCTN1, OCTN2 and OCT6/CT2 (20).  OCTN1 is a low affinity 
transporter for L-carnitine, but a high affinity transporter for ergothioneine, while both OCTN2 
and CT2 are high affinity transporters for L-carnitine (56, 62, 101).  L-carnitine in excess of 200-
fold did not block DNR uptake, thereby excluding these three transporters in the uptake of 
anthracyclines.  This is in stark contrast to the previous report by Okabe et al which described 
CT2 as a high affinity transporter for DOX, based on limited data from X. laevis oocytes injected 
with hCT2 cRNA, and Km measurements for DOX uptake  (76).  It remains inconclusive whether 
hCT2 cRNA produced a modified protein that indirectly promoted high affinity uptake of DOX 
since inhibition of DOX uptake and CT2 knockdowns were not conducted in their study (76).  
However, there is additional evidence that excludes the OCTN family as transporters of 
anthracyclines.  The leukemia cell line K562 does not express CT2 (Supplemental Fig. S5), yet 
these cells allow entry of DNR, thus eliminating the possibility that CT2 is involved in the 
transport of this drug (117).  Moreover, the HL60 cells expressed the CT2 transporter, but 
exhibited the slowest rate of DNR uptake.  It is noteworthy that the HL60 cells weakly expressed 
the OCT1 protein, while it is highly expressed in the K562 cells (Supplemental Fig. S3).  This 
observation is consistent with the notion that DNR uptake is directly proportional to the 
expression level of the OCT1 transporter.   
We note that OCTN1 was described previously as a high affinity transporter of ergothioneine 
(56) and subsequently, as a potential transporter of DOX based on gene expression analysis data 
from the NCI-60 panel of cell lines (59).  However, when the TOV2223G cells were challenged 
with a 200-fold excess of ergothioneine, there was only a partial effect on the uptake of DNR.  
Therefore, OCTN1 does not appear to have a major role in anthracycline uptake.  Our 
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observation of partial inhibition of DNR uptake by ergothioneine may be explained if human 
OCT1 also has a role in the uptake of this antioxidant.  This is consistent with reports describing 
C. elegans OCT-1 as a transporter for ergothioneine, and more recently, as a transporter for DOX 
(103, 114).   
Of the various competitors tested in this study, choline, an important component for the 
biogenesis of the plasma membrane and synthesis of the neurotransmitter acetylcholine (27), was 
the most effective in abolishing DNR uptake.  This is consistent with a previous report 
demonstrating that OCT1 displayed the ability to transport choline (98).  This raises the issue 
whether high affinity choline transporters in general have the ability to transport DNR.  Three 
different transport systems participate in choline uptake: the high affinity choline transporter 1, 
CHT1; the choline transporter like 1, CTL1; and the OCTs such as OCT1 and OCT2 (27).  
CHT1 has the highest affinity (Km of 1 µM) for choline uptake, while CTL1 is in the range of 25-
50 µM and OCT1 at nearly 42 µM (98).  The CHT1 transporter acts exclusively in neurons 
where it transports acetylcholine in a sodium-dependent manner.  Since the uptake of DNR is 
independent of sodium, it suggests that CHT1 is unlikely to be involved in DNR uptake.  CTL-1 
primarily transports choline in non-neuronal cells independent of sodium (118).  As such, both 
CTL-1 and OCT1 share common properties, however we did not examine whether shRNA 
against CTL-1 would further diminish the uptake of DNR in TOV2223G shRNA-OCT1 cells 
that were downregulated for OCT1 expression.  Other possibilities might exist to account for our 
finding that very low concentrations (0.5 to 5 µM) of choline can strongly compete for DNR 
uptake, if indeed both CTL-1 and OCT1 operates at low Km.  One possibility is that a high 
affinity sensor could sense the low level of choline and in turn negatively regulates the activity of 
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the lower affinity choline transporters such as OCT1 in a manner that has been reported for 
transceptors (119).    
Our findings could have direct impact on the chemotherapy regimen that is given to ovarian 
cancer patients.  There are four major types of primary ovarian adenocarcinoma and these are 
categorized as serous, mucinous, endometrioid, and clear-cell.  Serous adenocarcinoma 
comprises about one half of all ovarian cancers.  Currently, the combination of paclitaxel and 
cisplatin is the standard regimen for ovarian cancers with a response rate of nearly 70% (120).  
This combination of paclitaxel-platinum chemotherapy appears to improve overall and disease-
free survival not only for patients with primary ovarian cancer, but also for patients with relapsed 
disease (121).  Although treatment of this disease has improved, the 5-year survival of patients 
with advanced-stage ovarian cancer is less than 20%, and there is an ongoing effort to improve 
the outcome of treatment of ovarian cancer.  There is evidence that addition of DOX to the 
paclitaxel-platinum combination regimen can significantly improve survival of ovarian cancer 
patients (122-124).  However, the actual molecular mechanism leading to improved survival is 
not known.  Here, we propose that the expression level of OCT1 could dictate the added benefits 
for ovarian cancer patients receiving DOX together with the paclitaxel-platinum regimen, or to 
substitute paclitaxel with DOX in light of the observation that OCT1 can also transport paclitaxel 
(35).  This is in accordance with our results showing a better overall survival in high-grade 
serous ovarian cancer patients having high OCT1 mRNA levels, which could mediate increasing 
uptake of both platinum and paclitaxel (Fig. 7) (31, 35, 96).  OCT1 could also play a pivotal role 
in the outcome of other diseases that are treated with anthracyclines.  For example, patients with 
AML, a major cause of mortality from hematological malignancies in adults, are given a 
standard induction chemotherapy consisting of an anthracycline, such as DNR (125).  
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Importantly, a significant fraction (> 50 %) of older AML patients (> 60 yrs) do not achieve 
complete remission after the induction chemotherapy with DNR, and in some cases, remission 
lasts for a short duration due to drug resistance (88-90).  The underlying mechanisms that are 
responsible for DNR resistance in these AML non-responding patients are not known, although it 
is possible that one of the mechanisms could be due to a defect in the entry of the drug into the 
cancer cells.  Whether there are mutations that disrupt the function of OCT1 in a fraction of the 
AML non-responders, remains to be explored.  It should be noted that there are genetic 
polymorphisms in the OCT1 gene that altered, e.g., metformin uptake 
(https://www.pharmgkb.org/).  However, it is cumbersome to recreate the various mutations to 
test for alteration in DNR uptake, and instead we are screening DNR unresponsive AML patients 
for defective drug uptake and then establish whether these patients have mutations in the OCT1 
gene.
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MATERIALS AND METHODS 
Cell lines and cell culture—TOV2223G and OV866(2) were obtained from the RR Cancer-
Biobanque de cancer de l’ovaire du CHUM and are spontaneously immortalized cell lines 
derived from high-grade serous ovarian cancer patients’ solid tumor or ascites, respectively, 
and previously described (126)(Fleury et al., in press).  Cell lines were grown in OSE growth 
medium (Wisent, St-Bruno, QC) supplemented with 10% FBS, 2 mM L-glutamine, 0.5 μg/mL 
amphotericin B and 50 μg/mL gentamycin at 37°C, 5% CO2, 95% Air.  The leukemia cell lines 
HL60 and K562 were purchased from ATCC and kindly provided by Dr. Denis-Claude Roy 
(Maisonneuve-Rosemont Hospital research center) were grown in RPMI 1640 supplemented 
with 10% FBS, 2 mM L-glutamine, 100U/mL penicillin and 100µg/mL streptomycin at 37°C 
with 5% CO2.  The embryonic human kidney cell line HEK293T was kindly provided by Dr. 
El Bachir Affar (Maisonneuve-Rosemont Hospital research center) and grown in DMEM 
medium supplemented with 10% FBS, 2 mM L-glutamine, 100U/mL penicillin and 100µg/mL 
streptomycin at 37°C with 5% CO2.  
Antibodies, cDNA, vectors, and drugs—The SLC22A1 (NBP-59464) and β-Actin (AC-15) 
antibodies were purchased from Novus and Santa Cruz, CA, USA, respectively.  hSLC22A1 
cDNA (RDC0425) was purchased from R&D Systems.  The MSCV-LTRmiR30-PIG (LMP) 
vector was purchased from Thermo Scientific and pEYFP-N1 (6006-1) was purchased from 
Clontech.  Daunorubicin was purchased from Maisonneuve-Rosement Hospital, Montreal, 
Canada. 
Generation of hOCT1 shRNA for OCT1 knock down in TOV2223G cells—hOCT1 knock 
down was generated by two shRNA sequences obtained from the RNAi Central- RNAi Oligo 
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Retriever (http://katahdin.cshl.org:9331/homepage/siRNA/RNAi.cgi?type=shRNA; 
hannonlab.cshl.edu/GH_shRNA.html;) and listed in supplemental Table S1.  Among the two 
generated sequences, sequence 1 was able to most efficiently silence hOCT1 protein 
expression and was chosen for all subsequent studies.  The sense and antisense strands were 
linked with miR30 loop sequence and the miR-30 styled sequence was synthesized as a single 
stranded DNA oligonucleotide with one part corresponding to the endogenous miR-30 
miRNA flanking sequence.  The resulting 97-mer was PCR amplified using common miR30 
primers listed in supplemental Table S2 and subcloned into the EcoRI/ XhoI sites of MSCV-
LTRmiR30-PIG (LMP).  This generated the hOCT1 shRNA plasmid. 
Generation of hOCT1-EYFP fusion protein and the D474C variant—Human SLC22A1 
cDNA plasmid (RDC0425, R&D Systems, USA) containing the hOCT1 cDNA isoform 1 
(1678 bps) was used as template for PCR amplification with the primers listed in supplemental 
Table S2. The PCR product was subcloned into the XhoI/EcoRI sites of the mammalian 
expression vector, pEYFP-N1.  The resulting hOCT1-EYFP construct was amplified and 
positive clones were sequenced using sequencing primer.  The hOCT1-D474C-EYFP variant 
was created by site-directed mutagenesis using the primers listed in supplemental Table S2.  
DNR uptake assay—The day of the experiment, media was removed; cells were then washed 
with 2 mL Uptake buffer (125 mM NaCl, 10 mM HEPES pH 7.4, 5.6 mM glucose, 4.8 mM 
KCl, 1.2 mM KH2PO4, 1.2mM CaCl2, 1.2 mM MgSO4) for 5 min at gentle shaking and 
incubated in 1.9 mL of the same buffer for 20 min.  Drug uptake was initiated by the addition 
of 5 μM DNR.  DNR (5 mg/mL equivalent to 8.86 mM) was kept as a stock solution in water 
at -20 oC and diluted to 100 μM in uptake buffer.  Uptake was monitored over time, most often 
for 60 min at 37°C.  For competition studies, the competitor was mixed together with 5 μM 
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DNR and then added to the cells in the uptake buffer.  Uptake was stopped by directly adding 
2 mL ice cold uptake buffer to the drug-buffer complex or the drug-competitor-buffer complex 
which was immediately removed, followed by three successive washes with 2 mL of ice cold 
uptake buffer with gentle shaking for 5 min each. Cells were then collected by adding 0.25% 
Trypsin-EDTA to detach adherent cells (TOV2223G, OV866(2) and HEK293T) and 
centrifuged at 1000 x g for 5 min. 
Fluoroskan analysis–Cells treated as described were resuspended in 1 mL Uptake buffer 
prior to cell count or directly spin in the case of suspension cells HL60.  Cells (2 x 105)   were 
resuspended in 1 mL of Uptake buffer and 100 μL of resuspension (2x104 ) was added to each 
well in triplicate in a 96-well black well with optical bottom (Fisher Scientific). DNR cellular 
uptake was monitored with a microplate fluorometer (Fluoroskan Ascent, Thermo Scientific, 
USA) using tandem filter 544 nm excitation and 590 nm emission.   
Flow cytometry analysis–Cells were fixed with 100 μL of 4% paraformaldehyde (PFA) for 
10 min. Total cells were centrifuged to be resuspended in PBS (300 to 500 µl depending on 
the pellet size) then DNR cellular uptake was measured by FACScalibur, Becton-Dickinson 
(San Jose, CA).  In the case of simple DNR uptake assessment, 10 000 cells were analyzed 
with FL2 (585/42) as described previously.  In the case of overexpression with EYFP tag, 
55 000 cells (or total sample) were analyzed and cells expressing EYFP fluorescence were 
gated and the DNR fluorescence level was measured only for these EYFP expressing cells.  
For EYFP FL1 (530/30) was used and FL4 (670LP) was used for DNR fluorescence detection. 
Epifluorescence analysis for DNR uptake—Cells were grown in 6-well plates containing 18 
x 18-1 coverslips in 2 mL OSE complete medium and left to recover for 16 to 24 h.  The cells 
were treated with DNR as previously described then fixed with 100 μL of 4% PFA for 10 min.  
 66 
 
After fixation, cells were washed three times as described previously and mounted with 5 μL 
of mounting media (Vectashield, Vector Laboratories Inc., CA, USA) containing 1.5 μg/mL of 
4',6-diamidino-2-phenylindole (DAPI) on a microscope slide, and sealed with nail polish. 
Images were photographed with the Zeiss Z2 imager or the Olympus BX53 fluorescent 
microscope at 63 X and 60 X magnification, respectively, using DAPI/Texas Red filters.  
Images were then processed with Axio Vision (Zeiss Z2) or ImageJ (Olympus BX53) 
software. 
Epifluorescence analysis for hOCT1-EYFP overexpression—After overnight transfection 
in 6 well plate, the media was removed and HEK293T were briefly washed in PBS then 
collected by adding 0.25% Trypsin-EDTA. Cells were centrifuged and wash once in 1 ml PBS 
then fixed with 100 μL of 4% PFA for 10 min. After fixation, cells were washed once in PBS 
and resuspended in 30 μL of Vectashield mounting media containing 1.5 μg/mL 4',6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc., CA, USA). 7,5 µl of the 
suspension were put on a microscope slide.  Images were photographed with Zeiss Z2 imager 
at 63 X magnification using DAPI/ EYFP filters.  Images were then processed with Axio 
Vision software. 
shRNA transfection—TOV2223G cells were grown in 6-well plate in OSE complete media 
containing 10% FBS and antibiotics. When cells reached 60-70% confluence, media was 
replaced with fresh OSE media containing 10% FBS, but no antibiotics. 2.5 μg hOCT1 
shRNA pDNA were mixed with 7.5 μL Lipofectamine 2000(Life Technologies) in ratio 1:3. 
LMP shRNA pDNA was used as control vector.  Cells were selected with Puromycin 
(2μg/mL) for stable clones for 10 days before analysis.  
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Transfection of HEK293T cells for epifluorescence analysis—HEK293T cells at 60-70% 
confluence on coverslips in a 6-well plate were transfected overnight with one of three 
plasmids EYFP-N1, hOCT1-EYFP, hOCT1-D474C-EYFP and Lipofectamine 3000, as per 
manufacturer`s instructions.  Next day, they were processed for either DNR uptake assay 
analyzed by flow cytometry or fluorescence microscopy analysis. 
Rhodamine B (RhB) uptake assay—Transfected HEK293T cells were processed the same 
way as for DNR uptake assay but the 5 µM DNR were replaced by 50 µM RhB and 
FL2(585/42) was used to detect RhB fluorescence in FACS analysis of the samples 
Western Blot Analysis—Equal amounts of whole cell extract protein (30 μg) were separated 
by sodium dodecyl-polyacrylamide (SDS) polyacrylamide gel electrophoresis. Proteins were 
then transferred onto PVDF membrane and immunoblotted with anti-hOCT1 antibody at a 
1:1000 dilution in PBST buffer (137 mM NaCl, 2,7 mM KCl, 10 mM Na2HPO4, 1,8 mM 
KH2PO4, 0,1% Tween 20).  Equal protein loading was confirmed by reprobing the membrane 
with anti-β-Actin.  
MTT Assay—TOV2223G pLMP control vector and TOV2223G hOCT1 shRNA were seeded 
in a 96-well plate. Each well contained 7 x 103 cells per 100 μl with 5 μM DNR. After 72 
hours of incubation, 20 μL of  Methylthiazolyldiphenyl-tetrazolium bromide (MTT; Sigma-
Aldrich, Ltd, Ontario, Canada) concentrated at 5 mg/mL in uptake buffer, was added to each 
well and incubated for another 3 h at 37°C. The reaction was stopped by adding DMSO 
(Sigma lifesciences, Canada) in each well to dissolve the MTT crystals. Conversion of 
tetrazole into purple formazan product was detected at 540 nm, using the ELx808 Absorbance 
Microplate Reader (Biotek, Winooski, USA). All experiments were performed in triplicate. 
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Kinetic studies—TOV2223G cells were seeded at 2 x 104 cells per 100 μL with increasing 
concentrations of DNR. Initial rates were obtained by measuring uptake at 2.5 min, using the 
Fluoroskan Ascent Microplate reader set at 544 nm excitation/590 nm emission tandem filter. 
Measurements were expressed in relative fluorescence units (RFU). To estimate the kinetic 
parameters, uptake rates were fitted to the equation y =Vmax*x/(Km+x),  by means of 
nonlinear regression using GraphPad Prism(GraphPad Software Inc, CA, USA) in which Km 
and Vmax are Michaelis-Menten constant and maximum velocity respectively. The recorded 
RFUs were first multiplied by 1 x 10-4 L (100 μL), the total volume of buffer used to stop 
uptake, and then divided by 2.5 (time for uptake), and finally multiplied by 106 to give pmole 
DNR/2 x 104cells/min. 
Kaplan-Meier plotter analysis—The prognostic value of the SLC22A1 gene (hOCT1 
protein) in high-grade serous epithelial ovarian cancer was analyzed using the online tool 
Kaplan-Meier Plotter (http:/kmplot.com/analysis/), a database that integrates gene expression 
data and clinical information of breast, ovarian, lung and gastric cancers (109, 110).  Kaplan-
Meier Plotter uses three versions of the Affymetrix HG-U133 datasets (with 22,277 probe sets 
in common), and clinical data from Gene Expression Omnibus (GEO) and The Cancer 
Genome Atlas (TCGA) datasets.  The expression of SLC22A1 in the TCGA dataset for high-
grade serous epithelial ovarian cancer was verified with the best specific probe (JetSet probes) 
of this gene (207201_s_at).  A total of 469 patients were available for analysis on overall 
survival. Patient samples were split into two groups according to the median value, using the 
query parameter of auto-select best cutoff.  The signal range of the SLC22A1 probe was 1-
150, and the cutoff value was 19.  The two patient groups (high and low expression levels) 
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were compared using a Kaplan-Meier survival plot.  The hazard ratio with 95% confidence 
intervals and log rank p value was calculated, and significance was set at p < 0.05. 
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FIGURE LEGENDS 
FIGURE 1. Assessment of DNR uptake in cancer cell lines. After addition of DNR (5 µM) to 
cells, samples were harvested at the indicated time to monitor for the level of drug uptake.   A, 
Chemical structure of daunorubicin (DNR) obtained from 
https://www.ncbi.nlm.nih.gov/pccompound?term=daunorubicin.  B, Comparison of the 
relative uptake of DNR into four cancer cells using FACS analysis. Once the drug uptake was 
stopped, the washed cells were processed for FACS analysis.  A total of 10,000 cells were 
analyzed for DNR fluorescence using FL2 (585/42).  Results are expressed as the mean ± S.D. 
from three separate experiments.  C, Fluorescent spectrometry analysis of DNR uptake into 
TOV2223G, OV866(2), and HL60 cells.  The control (Ctrl) are TOV2223G cells without 
DNR.  Increased fluorescence denoting drug uptake was detected with Fluoroskan Ascent 
Microplate reader set at 544 nm excitation/590 nm emission.  The relative fluorescent unit 
(RFU) representing the measurement of drug uptake was expressed as pmol DNR/2 x104 cells/ 
min (see Material and Methods).  Results are expressed as the mean ± S.D. from three separate 
experiments.  D, Comparison of the concentration-dependent uptake of DNR by TOV2223G 
and HL60 cells.  Cells were incubated with indicated concentrations of DNR then analyzed by 
the Fluoroskan Ascent Microplate reader.  Results are expressed as the mean ± S.D. from three 
separate experiments.  E, Epifluorescent microscopy showing intracellular colocalization of 
DAPI and DNR in the TOV2223G cell line.  Comparisons were made between TOV2223G 
cells treated with or without DNR, followed by staining of nuclear DNA.  Following DNR 
uptake (5 µM), the cells were washed, fixed with paraformaldehyde and processed for 
microscopy using Vectashield mounting medium containing 1.5 μg/ml DAPI to detect the 
nuclear DNA.  Images were captured with an Olympus BX51 epifluorescent microscope using 
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Texas Red and DAPI-UV filters at 100 X magnification, and then processed with ImageJ 
software.  Merged images overlapped DAPI-stained nucleus (blue) with DNR staining (red).  
Results are representative of two separate experiments. 
 
FIGURE 2.  Kinetic analysis reveals a high affinity uptake for DNR into the TOV2223G 
cells.  Uptake rates were recorded for 60 min and quantified with the Fluoroskan Ascent 
microplate reader.  The data were fitted to the following equation y =Vmax*x/(Km+x) by 
means of nonlinear regression using GraphPad Prism (GraphPad Software Inc, CA, USA) to 
determine Michaelis-Menten constant and maximum velocity.  Results are representative of 
two separate experiments with standard errors. 
 
FIGURE 3. Choline, but not L-carnitine or ergothioneine, serves as a potent competitor in 
DNR uptake into the TOV2223G cells.  The cells were first seeded in 6-well plate onto 
coverslips at 5 x 105 cells in growth media and allowed to grow overnight.  The next day the 
media was removed and the attached cells were pre-incubated with uptake buffer for 20 min at 
37˚C. DNR (5 µM) and selected competitors at the indicated concentrations were mixed 
together in uptake buffer and added to cells on coverslips, followed by incubation for 1h.  
Cells were fixed and images were captured and processed as in Fig. 1E.  For panel E, the 
sodium chloride in the uptake buffer was substituted with N-methyl-D-glucamine. Choline 
denoted as CHL.  Results are representative of at least three separate experiments. 
 
FIGURE 4. Phenformin and thiamine partially inhibit DNR uptake in TOV2223G cells.  Cells 
were seeded in 96-well plates and DNR uptake was monitored as in Fig. 1C, but when added 
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together with either choline (CHL), ergothioneine (ERGO), phenoformin (PHEN), thiamine 
(THIA), spermidine (SPD) or L-carnitine (L-car).  Cells without DNR were designated as the 
control (Ctrl).  Results are expressed as the mean ± S.D. from three separate experiments. 
FIGURE 5. shRNA-OCT1 downregulation in TOV2223G cells diminishes DNR uptake and 
confers resistance to the drug.  A, Western blot analysis.  Total cell extracts were prepared 
from stable clones of TOV2223G cells carrying either the empty vector pLMP or the plasmid 
pshRNA-OCT1 and processed for Western Blot analysis using anti-hOCT1 antibody.  Each 
lane contained 30 µg of total protein extract.  Actin (ACT1) was used as the internal control.  
WT is the TOV2223G cells alone.  Results are representative of three separate experiments.  
B, Comparison of the concentration-dependent uptake of DNR into stable clones carrying 
either pLMP or pshRNA-OCT1.   DNR uptake was monitored using the Fluoroskan Ascent 
microplate reader as above.  Results are expressed as the mean ± S.D. from three separate 
experiments.  C, Epifluorescent microscopy reveals that OCT1 downregulation severely 
inhibits DNR uptake into TOV2223G cells.  The stable clones of TOV2223G carrying either 
pLMP or the knockdown plasmid pshRNA-OCT1 were fixed with PFA, and processed for 
microscopy, using Axio Imager Z2 with Texas Red and DAPI-UV filters at 63 X 
magnification.   Images were processed with AxioVision software.  Results are representative 
of three separate experiments.  D, Cell survival upon exposure to DNR.  The TOV2223G cells 
and stable clones carrying either the empty vector pLMP or pshRNA-OCT1 were exposed to 
DNR (5 µM) for 72 h, and the viability of the cells was monitored using MTT assay. Results 
are expressed as the mean ± S.D. from two separate experiments.  
FIGURE 6. Expression of OCT1-EYFP, but not the OCT1-D474C variant, increases DNR 
uptake in HEK293T cells.  The plasmid pOCT1-EYFP was used to create the OCT1-D474C 
 77 
 
mutation by site-directed mutagenesis.  The plasmids pEYFP (empty),  pOCT1-EYFP and 
pOCT1-D474C-EYFP were transiently transfected into HEK293T cells and exposed to DNR. 
Cells expressing EYFP were sorted to quantify the level of DNR uptake using FACS analysis 
using FL1 530/30 to detect EYFP fluorescence and FL4 670LP for DNR fluorescence.  A, 
Epifluorescent microscopy showing localization of the OCT1-EYFP fusion protein. Pictures 
were taken with Ziess Z2 fluorescent microcope using DAPI filter set and EYFP filter set.  
Results are representative of three separate experiments.   B, DNR uptake in HEK293T cells 
carrying either the plasmid pOCT1-EYFP, the variant, or the empty EYFP vector.  Results are 
expressed as the mean ± S.D. from three separate experiments.  C, Comparison of the 
rhodamine uptake level in HEK293T cells carrying the empty EYFP vector, or either the 
plasmid pOCT1-EYFP or pOCT1-D474C-EYFP.  Results are expressed as the mean ± S.D. 
from three separate experiments.  
FIGURE 7. High OCT1 mRNA levels are associated with better overall survival of high-
grade serous epithelial ovarian cancer patients.  Overall survival plot was generated online 
using the Kaplan-Meier Plotter based on signal intensity of the SLC22A1 probe (207201_s_at) 
in Affymetrix microarray gene expression data from high-grade serous epithelial ovarian 
cancer patients of The Cancer Genome Atlas.  Auto select best cutoff was chosen in the 
analysis; cutoff value was 19 and expression range of the probe was1-150.  A total of 469 
patients were available and samples were split in two groups (high and low) according to the 
cutoff value. The hazard ratio with 95% confidence intervals and log rank p value was 
calculated and significance was set at p < 0.05. 
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SUPPLEMENTAL DATA: 
 
 
Supplemental Table 1. The short hairpin sequences used in this study 
 
Sequence no sh sense 
sequence 
5’-3’  
sh entire sequence 
5’-3’ 
1 UGGCCACUGCCU
GAUUUCAAAC 
TGCTGTTGACAGTGAGCG(C)GGCCACTGCCTGA
TTTCAAACTAGTGAAGCCACAGATGTAGTTTGA
AATCAGGCAGTGGCCATGCCTACTGCCTCGGA 
2 ACCUCUUUCAGU
CCUGUUUGAA 
TGCTGTTGACAGTGAGCGCCCTCTTTCAGTCCT
GTTTGAATAGTGAAGCCACAGATGTATTCAAAC
AGGACTGAAAGAGGTTGCCTACTGCCTCGGA 
 
 
Supplemental Table 2. Oligonucleotides primers used in this study 
 
Primers Purpose Sequence 5’-3’ 
miR30-F Knockdown of OCT-1 CAGAAGGCTCGAGAAGGTATATT
GCTGTTGACAGTGAGCG 
miR30-R Knockdown of OCT-1 CTAAAGTAGCCCCTTGAATTCCG
AGGCAGTAGGCA 
hOCT-1-F hOCT-1-EYFP over 
expression 
AAATCAGATCTCGAGGCCGCCAC
CATGCCCACCGTGGATGAC 
hOCT-1-R2 hOCT-1-EYFP over 
expression 
ACCGTCGACTGCAGAATTCGGGT
GCCCGAGGGTTCAGAGGTTTGG 
Sequencing hOCT-1-EYFP 
construct sequencing 
CAAATGGGCGGTAGGCGTTG 
hOCT-1-
EYFP_D474C-F 
hOCT-1-EYFP site-
directed mutagenesis 
GTGTTCCTCCCTGTGTTGCATAGG
TGGGATAATCA 
hOCT-1-
EYFP_D474C-R 
hOCT-1-EYFP site-
directed mutagenesis 
TTATCCCACCTATGCAACACAGG
GAGGAACACACC 
 
 
  
  
FIGURE LEGENDS TO SUPPLEMENTAL DATA 
Figure S1. Epifluorescent microscopy showing DNR uptake into the nucleus of the ovarian 
cancer cell line OV866(2). 
Figure S2.  Epifluorescent microscopy showing DNR uptake under different conditions in the 
ovarian cancer cell line OV866(2). 
Figure S3.  Western blot analysis showing the expression level of OCT1 in various cancer cell 
lines.   
 Figure S4. Plasma membrane localization of native OCT1-EYFP and its variant OCT1-
D474C-EYFP.  
Figure S5.  RT-PCR analysis showing the expression level of CT2 (panel A) and OCTN2 
(panel B) in various leukemia cell lines and when cells were untreated and treated with DNR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental data Fig. S1. Epifluorescent microscopy showing DNR uptake into the nucleus  
of the ovarian cancer cell line OV866(2) 
 
 
 
 
  
Supplemental data Fig. S2.  Epifluorescent microscopy showing DNR uptake under  
different conditions in the ovarian cancer cell line OV866(2).  
 
 
 
 
 
 
 
 
  
Supplemental data Fig. S3.  Western blot analysis showing the expression level of OCT1  
in various cancer cell lines.    
 
 
 
 
 
 
 
 
 
  
 
Supplemental data Fig. S4. Plasma membrane localization of native OCT1-EYFP and its 
variant OCT1-D474C-EYFP.  
 
 
 
 
 
 
 
  
Supplemental data Fig. S5.  RT-PCR analysis showing the expression level of CT2 (panel A)  
and OCTN2 (panel B) in various leukemia cell lines and when cells were untreated and  
treated with DNR.    
 
 
 
 
 
  
Chapter 3: Discussion  
Anthracyclines: between passive diffusion, passive flip flop and facilitated transport 
mechanism. 
Interactions between the cellular plasma membrane and anticancer drugs are of great 
importance and determine the proper drug delivery in cancer cells. A majority of anticancer 
drugs are negatively charged and lipophilic, and it was therefore proposed that the transport of 
these drugs occurs by passive diffusion down a drug gradient or by a slow flip-flop 
mechanism which is defined as transmembrane lipid translocation (113). Indeed, biological 
membranes possess the ability to translocate (flip flop) lipid molecules across the outer and the 
inner leaflets of the plasma membrane and vice versa. The flipping, also referred as trans 
bilayer translocation is, however, energetically unfavorable for the cell because it would 
consume an enormous amount of energy (up to 50 kcal/mol) in order to overcome the energy 
barrier needed for phospholipid displacement (127). It was shown that very slow spontaneous 
flipping with a half-life of hours to days does not occur in biogenic membranes; rather this 
process occurs very fast with rates from tens of seconds to several minutes, suggesting the 
involvement of specific transport systems (127). One possible way for this to occur is via 
specialized proteins called flippases, but the identification of such « flipping helpers» for 
anthracyclines translocation has not yet been discovered. Members of the ABC transporters 
such P-glycoprotein are believed to act as flippases and there is an ongoing debate that the 
resistance vs sensitivity of cancer cells towards anthracyclines depends on MDR protein 
expression, but  a recent study using the specific P-glycoprotein inhibitor valspodar (PSC-833) 
clearly showed that anthracyclines entry is independent of MDR expression pattern or action 
(93). Thus DNR, DOX or other anthracyclines cannot cross the plasma membrane, as they 
would be exclusively located at the cell surface. Indeed, our results (figure 1) showing a 
differential uptake of DNR in various cell lines supports this notion and, although there is no 
additional evidence, uptake of DNR by passive diffusion or flip-flop should otherwise be seen 
equally in every cell line tested. In the present study we show that DNR transport depends on 
OCT1 protein expression and TOV2223G cells deficient in OCT1 expression (figure 5) 
display a substantially decreased DNR transport. Whether OCT1 is physically responsible for 
  
further delivering anthracyclines to their final destination, the nucleus, remains to be explored. 
Hence, the discovery of OCT1 as functional and high affinity transporter for the anthracycline 
DNR would be a valuable asset for screening patients cytogenetic responses towards this 
chemotherapeutic drug.  
 
OCT1 is critical for DNR uptake and may be used as prognostic marker for 
responsiveness to therapy with anthracyclines. 
Chemoresistance to anticancer drugs is an actual challenge for the successful outcome of 
therapy and OCT1 has an important role to play in this regard. More et al., (30) demonstrated 
that functional OCT1 transporter is needed for a proper transport of picoplatin in HEK293T 
cells. Moreover, it was shown that structural differences in platinum derivatives have a great 
impact on drug interactions with OCT1, and variations in protein composition appear to affect 
the uptake of platinum compounds such as oxaliplatin. Therefore, it was suggested that OCT1 
plays an important role in chemoresistance in various cancers including colon cancer (30). 
Another group working on OCT1 and metformin transport reported that this transporter is 
crucial for uptake of the drug in OVCAR-3 and SKOV-3 ovarian cell lines (30). It was 
demonstrated that metformin combined with cisplatin seems to have a synergic effect on 
apoptosis. The authors of this study also demonstrated that differential expression of OCT1 is 
a strong determinant of sensitivity to the metformin therapy and suggested the use of 
phenformin (128). Our in vitro results showing a direct role of OCT1 in the transport of DNR 
in TOV2223G may have an important clinical impact in terms of predicating patient response 
to anthracyclines. Indeed, data obtained from our in vivo study (figure 7) investigating the role 
of OCT1 in overall survival of relapsed/recurrent ovarian cancer patients comparing 469 
patients samples treated with combinational chemotherapy with cisplatin and paclitaxel and 
differing by the expression level of OCT1, clearly show that patients overexpressing OCT1 
display an increased survival probability compared to control which suggests that 
overexpression of this transporter favors tumor eradication. TOV2223G is a serous type, solid 
tumor ovarian cancer cell line model and this type of cancer accounts for one half of all 
ovarian cancers including mucinous, endometria and clear-cell. Serous type ovarian cancer 
patients are initially subjected to surgery and as these are mostly diagnosed with advanced 
  
stage of tumor growth and spread, its removal is extremely difficult and mostly inefficient. 
When surgery fails, patients are then subjected to a first line chemotherapy of standard 
regimen including combinational treatment with carboplatin/cisplatin and paclitaxel (CP) 
(129). PEGylated DOX (PD) is currently used in clinical trials such as CALYPSO (Caelyx in 
Platinum Sensitive Ovarian patients) (130, 131). In this study, PD in combination with 
carboplatin (investigated arm) was compared to CP alone (control arm) and the results showed 
a statistically significant improvement in progression free survival (PFS) in the investigated 
arm (131). Although the study did not profile patients for OCT1 expression, a possible role of 
OCT1 should be considered as it can transport DNR and paclitaxel. Therefore, we propose that 
OCT1 expression levels should be monitored in order to predict better responsiveness to PD 
treatment. PD, which was approved in both Europe and USA (Caelyx, EU and Doxil, USA) 
has garnered particular attention with respect to treatment of ovarian cancer, breast cancer and 
multiple myelomas (data from EMA).  It is noteworthy that the efficiency of the liposomal PD 
formulation may suggest that entry of the drug occurs via passive diffusion or by flip flop 
mechanism. As DOX-HCl in PD is encapsulated by a surface-bound methoxy polyethylene 
glycol (mPEG), the hydrophilic shell of the latter appears to contribute to a prolonged blood 
circulation half-life of the drug and as a consequence is less targeted to  mononuclear cells 
such as macrophages compared to the conventional DOX-HCl formulation (132). Moreover, it 
was shown that PD locates at the extracellular fluid surrounding the tumor cell without 
entering it, where the liposomes release their cargo DOX (132). Therefore, the entry of the 
free drug must occur via a facilitated transport mechanism, and based on our findings, we 
believe that this occurs via the transporter OCT1.   
Conclusion and future directions 
Further studies are needed in order to demonstrate that OCT1 is indeed crucial for DNR 
transport. Although we clearly show that DNR is a high affinity substrate for OCT1, we do not 
exclude the contribution of low affinity DNR transporters such as OCT2 and OCT3 as these 
share 75%-85% and 50% identity in protein sequence respectively. In support of this is the 
residual uptake of DNR that we observed in TOV2223G down regulated for OCT1. Moreover, 
as DNR uptake was blocked substantially with choline, and because of the reported role of 
OCT2 in choline transport, a role for OCT2 in DNR transport may also be suggested. 
  
However, if OCT2 was also involved in choline transport, down regulation of OCT1 in 
TOV2223G should not be sufficient for efficient inhibition of DNR transport, as the latter 
should occur predominantly via OCT2 and therefore we would be able to observe fluorescent 
DNR inside the cell. Since we did not observe DNR uptake in TOV2223G cells lacking 
OCT1, we believe that OCT2 is not involved in choline and DNR transport. We also exclude 
the contribution of CHT1 transporter in DNR transport because choline transport in 
TOV2223G is sodium independent (data not shown) and sodium import is absolute 
requirement for CHT1 to operate. It is noteworthy that although the lack of OCT1 greatly 
prevented the entry of DNR, we cannot rule out the possibility that choline transport was 
available for uptake by another transporter. Unfortunately, either in control cells or in cells 
with down regulated OCT1, we could not quantify choline uptake by fluorescence microscopy 
or fluorometric micro plate reader. To overcome this, one possibility would be the use of the 
fluorescent choline derivatives ethanamimium 2-hydroxy-N,N-dimethyl-N-[2-N-(2,1,3-
benzoxadiazol-4-amine,-N-methyl,-7- nitro)-ethyl] bromide (NBD-choline) and C6–NBD–
phosphatidylcholine (C6–NBD–PC) as suggested by Vila et al., (133). The authors reported 
that these two derivatives have the ability to only enter cancer cells and not normal cells, 
which might be an important asset for screening deregulation of choline transport. 
Nevertheless, we do not exclude the possibility of inefficient knock down of OCT1 and we 
believe that an absolute depletion of this transporter will be needed in order to confirm its 
particular role in the transport of DNR. Thus, we intend to knock out OCT1 using the 
CRISPR-Cas9 system in TOV2223G which, we believe, will confirm the role of OCT1 as 
high affinity transporter of DNR. Moreover, as OCT2 and OCT3 might also be involved in 
DNR uptake as supportive DNR transporters, knock down of both transporters might not be 
indicative of their contribution in DNR transport, but might be indicative of increased OCT1 
protein expression on the cell surface. We exclude the contribution of OCTN1, OCTN2 and 
CT2 as DNR transporters, because high affinity substrates for these transporters did not block 
DNR uptake either in TOV2223G (figure 4) or in other tested cell lines (data not shown). In 
support of this is the low protein identity with OCT1 (~30%) which suggests a different role of 
these transporters other than in the transport of anthracyclines.  
 
  
References 
1. Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: 
serendipity and chemical biology. Chemistry & biology. 2013;20(5):648-59. 
2. Oronsky BT, Carter CA, Oronsky AL, Salacz ME, Reid T. "No patient left behind": an 
alternative to "the War on Cancer" metaphor. Medical oncology (Northwood, London, 
England). 2016;33(6):55. 
3. Rosenberg B, Vancamp L, Krigas T. INHIBITION OF CELL DIVISION IN 
ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM 
ELECTRODE. Nature. 1965;205:698-9. 
4. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the 
clinic and in clinical trials. Dalton transactions (Cambridge, England : 2003). 
2010;39(35):8113-27. 
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews 
Cancer. 2007;7(8):573-84. 
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular 
advances and pharmacologic developments in antitumor activity and cardiotoxicity. 
Pharmacological reviews. 2004;56(2):185-229. 
7. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Seminars in 
oncology. 1992;19(6):670-86. 
8. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic-
pharmacodynamic relationships of the anthracycline anticancer drugs. Clinical 
pharmacokinetics. 2002;41(6):431-44. 
9. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin 
dynamics. Biochimica et biophysica acta. 2014;1845(1):84-9. 
10. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced 
cardiotoxicity. Free radical biology & medicine. 1997;23(5):775-82. 
11. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 
years after completing anthracycline therapy. Jama. 1991;266(12):1672-7. 
12. Hefti E, Blanco JG. Anthracycline-Related Cardiotoxicity in Patients with Acute 
Myeloid Leukemia and Down Syndrome: A Literature Review. Cardiovascular toxicology. 
2015. 
13. Borchmann P, Hubel K, Schnell R, Engert A. Idarubicin: a brief overview on 
pharmacology and clinical use. International journal of clinical pharmacology and 
therapeutics. 1997;35(2):80-3. 
14. Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H. Apoptosis in 
young rats with adriamycin-induced cardiomyopathy--comparison with pirarubicin, a new 
anthracycline derivative. Pediatric research. 2002;51(2):256-9. 
15. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac 
transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Annals 
of hematology. 2002;81(9):504-7. 
16. Sharom FJ. ABC multidrug transporters: structure, function and role in 
chemoresistance. Pharmacogenomics. 2008;9(1):105-27. 
17. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting 
multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-34. 
  
18. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system 
and cardiovascular drugs. Journal of the American College of Cardiology. 2013;61(25):2495-
502. 
19. Homolya L, Orban TI, Csanady L, Sarkadi B. Mitoxantrone is expelled by the ABCG2 
multidrug transporter directly from the plasma membrane. Biochimica et biophysica acta. 
2011;1808(1):154-63. 
20. Koepsell H. The SLC22 family with transporters of organic cations, anions and 
zwitterions. Molecular aspects of medicine. 2013;34(2-3):413-35. 
21. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, 
function, physiological roles, and biopharmaceutical implications. Pharmaceutical research. 
2007;24(7):1227-51. 
22. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion 
mediated by a new prototype of polyspecific transporter. Nature. 1994;372(6506):549-52. 
23. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, et al. OCT1 is a high-capacity 
thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings 
of the National Academy of Sciences of the United States of America. 2014;111(27):9983-8. 
24. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of 
genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal 
of clinical investigation. 2007;117(5):1422-31. 
25. Kim MH, Maeng HJ, Yu KH, Lee KR, Tsuruo T, Kim DD, et al. Evidence of carrier-
mediated transport in the penetration of donepezil into the rat brain. Journal of pharmaceutical 
sciences. 2010;99(3):1548-66. 
26. Murakami H, Sawada N, Koyabu N, Ohtani H, Sawada Y. Characteristics of Choline 
Transport Across the Blood-Brain Barrier in Mice: Correlation with In Vitro Data. 
Pharmaceutical research. 2000;17(12):1526-30. 
27. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid 
synthesis. Experimental biology and medicine (Maywood, NJ). 2006;231(5):490-504. 
28. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. Selective substrates for 
non-neuronal monoamine transporters. Molecular pharmacology. 1999;56(1):1-10. 
29. Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport: a role for organic 
cation transporter 2 expressed in choroid plexus. The Journal of biological chemistry. 
2001;276(45):41611-9. 
30. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, et al. Organic cation transporters 
modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. 
Molecular cancer therapeutics. 2010;9(4):1058-69. 
31. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation 
transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847-57. 
32. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of 
organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in 
colorectal cancer. Drug metabolism and disposition: the biological fate of chemicals. 
2008;36(11):2299-306. 
33. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT-
1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib 
(AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 
2006;108(2):697-704. 
  
34. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new 
formulations. Drug design, development and therapy. 2012;6:371-84. 
35. Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. Human organic 
cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan 
and paclitaxel. J Pharmacol Exp Ther. 2012;341(1):16-23. 
36. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional 
expression of a novel rat kidney organic cation transporter, OCT2. Biochemical and 
biophysical research communications. 1996;224(2):500-7. 
37. Cetinkaya I, Ciarimboli G, Yalcinkaya G, Mehrens T, Velic A, Hirsch JR, et al. 
Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-
dependent kinases. American journal of physiology Renal physiology. 2003;284(2):F293-302. 
38. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene 
expression levels and immunolocalization of organic ion transporters in the human kidney. 
Journal of the American Society of Nephrology : JASN. 2002;13(4):866-74. 
39. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester 
S, et al. Cloning and characterization of two human polyspecific organic cation transporters. 
DNA and cell biology. 1997;16(7):871-81. 
40. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes 
the degree of substrate ionization. The Journal of biological chemistry. 2002;277(25):22491-6. 
41. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of 
the corticosterone-sensitive extraneuronal catecholamine transporter. Nature neuroscience. 
1998;1(5):349-51. 
42. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the 
organic cation transporter 2 influence the disposition of metformin. Clinical pharmacology and 
therapeutics. 2008;84(5):559-62. 
43. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. 
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. 
Pharmacogenetics. 2002;12(5):395-405. 
44. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al. Metformin is a 
superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug 
metabolism and pharmacokinetics. 2005;20(5):379-86. 
45. Shih MC, Hoexter MQ, Andrade LA, Bressan RA. Parkinson's disease and dopamine 
transporter neuroimaging: a critical review. Sao Paulo medical journal = Revista paulista de 
medicina. 2006;124(3):168-75. 
46. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. 
Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron 
emission tomography study. Annals of neurology. 2007;62(5):468-74. 
47. Taubert D, Grimberg G, Stenzel W, Schömig E. Identification of the Endogenous Key 
Substrates of the Human Organic Cation Transporter OCT2 and Their Implication in Function 
of Dopaminergic Neurons. PLoS ONE. 2007;2(4):e385. 
48. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. 
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. 
Clinical pharmacology and therapeutics. 2009;86(4):396-402. 
49. Tanihara Y, Masuda S, Katsura T, Inui K. Protective effect of concomitant 
administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic 
cation transporter OCT2. Biochem Pharmacol. 2009;78(9):1263-71. 
  
50. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, et al. Cloning and 
functional characterization of a potential-sensitive, polyspecific organic cation transporter 
(OCT3) most abundantly expressed in placenta. The Journal of biological chemistry. 
1998;273(26):15971-9. 
51. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, et al. Identity of the organic 
cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence 
for the expression of the transporter in the brain. The Journal of biological chemistry. 
1998;273(49):32776-86. 
52. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, et al. 
Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. The 
Journal of biological chemistry. 1998;273(47):30915-20. 
53. Courousse T, Gautron S. Role of organic cation transporters (OCTs) in the brain. 
Pharmacology & therapeutics. 2015;146:94-103. 
54. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, et al. Expression 
of human organic cation transporter 3 in kidney carcinoma cell lines increases 
chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009;69(4):1494-501. 
55. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, et al. Cloning and 
characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS 
letters. 1997;419(1):107-11. 
56. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, et al. Discovery 
of the ergothioneine transporter. Proceedings of the National Academy of Sciences of the 
United States of America. 2005;102(14):5256-61. 
57. Grundemann D. The ergothioneine transporter controls and indicates ergothioneine 
activity--a review. Preventive medicine. 2012;54 Suppl:S71-4. 
58. Pochini L, Scalise M, Galluccio M, Indiveri C. OCTN cation transporters in health and 
disease: role as drug targets and assay development. Journal of biomolecular screening. 
2013;18(8):851-67. 
59. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, et al. Profiling SLCO 
and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. 
Molecular cancer therapeutics. 2008;7(9):3081-91. 
60. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ. Oxaliplatin transport mediated 
by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human 
embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 
2011;338(2):537-47. 
61. Sekine T, Kusuhara H, Utsunomiya-Tate N, Tsuda M, Sugiyama Y, Kanai Y, et al. 
Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. 
Biochemical and biophysical research communications. 1998;251(2):586-91. 
62. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, et al. Molecular and 
functional identification of sodium ion-dependent, high affinity human carnitine transporter 
OCTN2. The Journal of biological chemistry. 1998;273(32):20378-82. 
63. Wu X, Prasad PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and 
genomic organization of human OCTN2, a new member of the organic cation transporter 
family. Biochemical and biophysical research communications. 1998;246(3):589-95. 
64. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, et al. Regional 
distribution of solute carrier mRNA expression along the human intestinal tract. Drug 
metabolism and disposition: the biological fate of chemicals. 2007;35(4):590-4. 
  
65. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, et al. 
Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. 
American journal of respiratory cell and molecular biology. 2007;36(1):53-60. 
66. Garrett Q, Xu S, Simmons PA, Vehige J, Flanagan JL, Willcox MD. Expression and 
localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium. 
Investigative ophthalmology & visual science. 2008;49(11):4844-9. 
67. Tamai I. Pharmacological and pathophysiological roles of carnitine/organic cation 
transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharmaceutics & drug 
disposition. 2013;34(1):29-44. 
68. Lee H-J, Zheng JJ. PDZ domains and their binding partners: structure, specificity, and 
modification. Cell Communication and Signaling : CCS. 2010;8:8-. 
69. Lahjouji K, Elimrani I, Lafond J, Leduc L, Qureshi IA, Mitchell GA. L-Carnitine 
transport in human placental brush-border membranes is mediated by the sodium-dependent 
organic cation transporter OCTN2. American journal of physiology Cell physiology. 
2004;287(2):C263-9. 
70. Maekawa S, Mori D, Nishiya T, Takikawa O, Horinouchi T, Nishimoto A, et al. 
OCTN2VT, a splice variant of OCTN2, does not transport carnitine because of the retention in 
the endoplasmic reticulum caused by insertion of 24 amino acids in the first extracellular loop 
of OCTN2. Biochimica et biophysica acta. 2007;1773(6):1000-6. 
71. Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, et al. Inhibition of OCTN2-
mediated transport of carnitine by etoposide. Molecular cancer therapeutics. 2012;11(4):921-9. 
72. Duran JM, Peral MJ, Calonge ML, Ilundain AA. OCTN3: A Na+-independent L-
carnitine transporter in enterocytes basolateral membrane. Journal of cellular physiology. 
2005;202(3):929-35. 
73. Lamhonwah AM, Ackerley CA, Tilups A, Edwards VD, Wanders RJ, Tein I. OCTN3 
is a mammalian peroxisomal membrane carnitine transporter. Biochemical and biophysical 
research communications. 2005;338(4):1966-72. 
74. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, et al. Molecular 
identification of a novel carnitine transporter specific to human testis. Insights into the 
mechanism of carnitine recognition. The Journal of biological chemistry. 
2002;277(39):36262-71. 
75. Sato N, Ito K, Onogawa T, Akahira J, Unno M, Abe T, et al. Expression of organic 
cation transporter SLC22A16 in human endometria. Int J Gynecol Pathol. 2007;26(1):53-60. 
76. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, et al. Characterization of 
the organic cation transporter SLC22A16: a doxorubicin importer. Biochemical and 
biophysical research communications. 2005;333(3):754-62. 
77. Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O, et al. Organic cation 
transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer 
chemotherapy and pharmacology. 2015. 
78. Aouida M, Poulin R, Ramotar D. The human carnitine transporter SLC22A16 mediates 
high affinity uptake of the anticancer polyamine analogue bleomycin-A5. The Journal of 
biological chemistry. 2010;285(9):6275-84. 
79. Aouida M, Leduc A, Poulin R, Ramotar D. AGP2 encodes the major permease for high 
affinity polyamine import in Saccharomyces cerevisiae. The Journal of biological chemistry. 
2005;280(25):24267-76. 
  
80. Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, et al. Expression of organic 
cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the 
adriamycin importer. Int J Gynecol Pathol. 2007;26(3):334-40. 
81. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, et al. Novel SLC22A16 
polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer 
patients. Pharmacogenomics. 2007;8(6):567-75. 
82. Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Reviews of 
physiology, biochemistry and pharmacology. 2003;150:36-90. 
83. Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, et al. The organic 
anion transporter (OAT) family: a systems biology perspective. Physiological reviews. 
2015;95(1):83-123. 
84. Ahn SY, Eraly SA, Tsigelny I, Nigam SK. Interaction of organic cations with organic 
anion transporters. The Journal of biological chemistry. 2009;284(45):31422-30. 
85. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015;14(1):29-
44. 
86. Westmoreland TJ, Wickramasekara SM, Guo AY, Selim AL, Winsor TS, Greenleaf 
AL, et al. Comparative genome-wide screening identifies a conserved doxorubicin repair 
network that is diploid specific in Saccharomyces cerevisiae. PLoS One. 2009;4(6):e5830. 
87. Lown JW. Anthracycline and anthraquinone anticancer agents: current status and 
recent developments. Pharmacology & therapeutics. 1993;60(2):185-214. 
88. Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol. 
2001;13(1):21-6. 
89. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 
2001;13(6):463-9. 
90. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. 
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative 
incidence of relapse, and overall survival in adult patients with de novo acute myeloid 
leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 
2002;100(13):4325-36. 
91. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods 
Mol Biol. 2010;596:47-76. 
92. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter 
superfamily. Journal of lipid research. 2001;42(7):1007-17. 
93. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein 
inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than 
age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B 
study 19808. Blood. 2010;116(9):1413-21. 
94. Aouida M, Leduc A, Wang H, Ramotar D. Characterization of a transport and 
detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. 
Biochem J. 2004;384(Pt 1):47-58. 
95. Aouida M, Page N, Leduc A, Peter M, Ramotar D. A genome-wide screen in 
Saccharomyces cerevisiae reveals altered transport as a mechanism of resistance to the 
anticancer drug bleomycin. Cancer Res. 2004;64(3):1102-9. 
96. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not 
carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 
and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319(2):879-86. 
  
97. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. 
Genetic variation in the organic cation transporter 1 is associated with metformin response in 
patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242-7. 
98. Sinclair CJ, Chi KD, Subramanian V, Ward KL, Green RM. Functional expression of a 
high affinity mammalian hepatic choline/organic cation transporter. Journal of lipid research. 
2000;41(11):1841-8. 
99. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular 
multidrug resistance. FASEB J. 2001;15(3):719-30. 
100. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, et al. 
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-
performance liquid chromatography. Anal Biochem. 1999;266(2):216-21. 
101. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, et al. Molecular 
identification of a novel carnitine transporter specific to human testis. Insights into the 
mechanism of carnitine recognition. J Biol Chem. 2002;277(39):36262-71. 
102. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al. Primary systemic 
carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine 
transporter. Nat Genet. 1999;21(1):91-4. 
103. Cheah IK, Ong RL, Gruber J, Yew TS, Ng LF, Chen CB, et al. Knockout of a putative 
ergothioneine transporter in Caenorhabditis elegans decreases lifespan and increases 
susceptibility to oxidative damage. Free Radic Res. 2013;47(12):1036-45. 
104. Sala-Rabanal M, Li DC, Dake GR, Kurata HT, Inyushin M, Skatchkov SN, et al. 
Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. 
Mol Pharm. 2013;10(4):1450-8. 
105. Azam S, Drobetsky E, Ramotar D. Overexpression of the cis/trans isomerase PTPA 
triggers caspase 3-dependent apoptosis. Apoptosis. 2007;12(7):1243-55. 
106. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump 
inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One. 
2011;6(7):e22163. 
107. Gorbunov D, Gorboulev V, Shatskaya N, Mueller T, Bamberg E, Friedrich T, et al. 
High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and 
blocks transport after mutations in a modeled interaction domain between two helices. Mol 
Pharmacol. 2008;73(1):50-61. 
108. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. 
109. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online 
survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis 
using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725-31. 
110. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide 
validation of survival-associated biomarkers in ovarian-cancer using microarray data from 
1287 patients. Endocr Relat Cancer. 2012;19(2):197-208. 
111. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, 
MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp 
Pharmacol. 2011(201):105-67. 
112. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. 
Structural requirements for drug inhibition of the liver specific human organic cation transport 
protein 1. J Med Chem. 2008;51(19):5932-42. 
  
113. Dupou-Cezanne L, Sautereau AM, Tocanne JF. Localization of adriamycin in model 
and natural membranes. Influence of lipid molecular packing. Eur J Biochem. 
1989;181(3):695-702. 
114. Brosseau N, Andreev E, Ramotar D. Complementation of the Yeast Model System 
Reveals that Caenorhabditis elegans OCT-1 Is a Functional Transporter of Anthracyclines. 
PLoS One. 2015;10(7):e0133182. 
115. Courousse T, Bacq A, Belzung C, Guiard B, Balasse L, Louis F, et al. Brain organic 
cation transporter 2 controls response and vulnerability to stress and GSK3beta signaling. Mol 
Psychiatry. 2015;20(7):889-900. 
116. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic 
cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and 
cholestasis in human liver. Hepatology. 2009;50(4):1227-40. 
117. Fadili KE, Andreev E, Wang Z, Ramotar D. Cellular Responses to Anthracyclines 
Identify Ku70, a DNA Repair Factor that Changes Compartment and Remains Stable in 
Leukemic Cells. American Journal of Cancer Science. 2013;2:73-87. 
118. Taguchi C, Inazu M, Saiki I, Yara M, Hara N, Yamanaka T, et al. Functional analysis 
of [methyl-(3)H]choline uptake in glioblastoma cells: Influence of anti-cancer and central 
nervous system drugs. Biochem Pharmacol. 2014;88(3):303-12. 
119. Kriel J, Haesendonckx S, Rubio-Texeira M, Van Zeebroeck G, Thevelein JM. From 
transporter to transceptor: signaling from transporters provokes re-evaluation of complex 
trafficking and regulatory controls: endocytic internalization and intracellular trafficking of 
nutrient transceptors may, at least in part, be governed by their signaling function. Bioessays. 
2011;33(11):870-9. 
120. van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, et al. 
Long-term results of a randomised phase III trial of weekly versus three-weekly 
paclitaxel/platinum induction therapy followed by standard or extended three-weekly 
paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J 
Cancer. 2014;50(15):2592-601. 
121. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et 
al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based 
chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. 
Lancet. 2003;361(9375):2099-106. 
122. Kim JE, Jang MJ, Jin DH, Chung YH, Choi BS, Park GB, et al. Paclitaxel-exposed 
ovarian cancer cells induce cancerspecific CD4+ T cells after doxorubicin exposure through 
regulation of MyD88 expression. Int J Oncol. 2014;44(5):1716-26. 
123. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J 
Clin Oncol. 1995;13(3):726-32. 
124. Hess V, Verrill MW, Bomphray CC, Vaughan MM, Allen M, Gore ME. Phase I study 
of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian 
carcinoma. Ann Oncol. 2003;14(4):638-42. 
125. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. 
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an 
international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-
74. 
  
126. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, et al. 
Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer. 
2008;8:152. 
127. Pomorski T, Menon AK. Lipid flippases and their biological functions. Cellular and 
molecular life sciences : CMLS. 2006;63(24):2908-21. 
128. Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. 
Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochemical and 
biophysical research communications. 2011;414(4):694-9. 
129. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey 
PA, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and 
Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 
2010;28(20):3323-9. 
130. Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, et al. 
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially 
platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO 
phase III trial. Ann Oncol. 2012;23(5):1185-9. 
131. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall 
survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and 
carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British 
journal of cancer. 2012;107(4):588-91. 
132. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, 
rationale, and clinical applications, existing and potential. International journal of 
nanomedicine. 2006;1(3):297-315. 
133. Villa AM, Caporizzo E, Papagni A, Miozzo L, Del Buttero P, Grilli MD, et al. Choline 
and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by 
laser scanning confocal fluorescence microscopy. Eur J Cancer. 2005;41(10):1453-9. 
 
